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and diabetic ketoacidosis, ^186-187 
lactic and pyruvic acids 
and diabetic coma, °350 
lipids ,. 
in monkeys, 1084-1Ö86 / 
lipoproteins 
in combined hyperlipoproteinemia, 
•376 
lymphocytes 
response to phytöhemägglutinin and 
Candida albicans antigen, 
906-907 
lymphocytes, and fibroblasts 
insulin binding to, 426-427 . 
C-peptide, 661-670 ' 
platelet aggregation, 
and diabetes, 108-112; *355 
and glucagon, °311-312 
platelets • ! ' -
and diabetic retinopathy, •120-121 
and fatty acid metabolism, °312 
proinsulin, 66i-670 ' 
prothrombin time 
and vitamin K, ,*183 , , , 
samples 
and responses to amino acids in mal-
nourished infants, •182 
in study of diabetes in Mystromys 
albicaudatus, 716 
and sulfonylurea study, 217-223 
transfusions ' 
and glucose, •1120" 1 *• ' 
viscosity 
and juvenile diabetics, »254 
BLOOD GLUCOSE) See also Blood 
sugar 
and alloxan -
, and diphenylhydantoin and gluta-
r., . thione, 80-83 , 
and 6-aminonicotinamicle, 144-148 
and arginine* 308-310 
assays . t 
and surgery for islet cell adenomas, 
•185 
and body weight, •362-363 
capillary and venous, 1103-1105, 1107 
control 
and vascular diseases, 976-978 
determination 
and reflectance meter/enzyme test 
.. ..strip system, *1119 
and diabetic instability^ >• 836 
and diet 
in obese hyperglycemic mice, ?119 
diurnal • 
and unstable diabetes, • 1203 
and exercise . . 
and diabetes,^89-99 
and .obesity, *9(j9 
in female diabetic rats 
and fetal pancreatic transplants, 199-
<• : 200' M ' 
and glucose dosage, 1103-1104 
and insulin 
in diabetics and nondiabetics, *1047 
and insulin administration to gastro-
intestinal tract, 203-207 
and insulinoma, *250 , ; : 
and ketoacidosis, *181 
and lipoatrophic diabetes, 827-830 , 
and metformin, •771 , . 
monitoring, 705-706 • 
plasma immunoreactive insulin dur-
ing, °324-325 
and oral insulin, 644-647 
and plasma growth hormone . 
and diabetic retinopathy, /*322 
production and oxidation \ 
and insulin-dependent diabetes,, °375 
and propranolol, *122 
response to catecholamines 
and noradrenaline and, adrenaline, 
- V ; ^12 ' ;'; . 
response to glucagon,., glucose and tol-
butamide 
and, liver xirrnosis and insulinemia, 
. I •121-122 
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BLOOD PRESSURE, See alsa Hyper-
tension 
and kidney transplantation 
and diabetes, *322 
BLOOD SUGAR 
and atherosclerosis, *253 
control, 834 
and nerve tissue sorbitol and fruc-
tose, 1173-1178, 
determination 
and Ames reflectance meter, *1120 
and diabetic pregnancy outcome, 
•1201-1202 
in diabetes survey, 1193-1196 
formation , • 
and lactate, *189 
and glucagon infusion 
in congestive heart failure patients, 
940-944 ; 
and glycosuria 
and insulin, *186 
and insulin stability, 812 
and nialamide, *363464 
in normals and prediabetics, *383 
and pancreas extract injection in de-
pancreatized dogs '•• 
and discovery of insulin, 386-395 
and phenobarbitone, *1123 
and sulfonylureas, *1120 
and kidney failure, ^1120-1121 
and uterine relaxants, * 1045 ; 
BLOOD VESSELS. See Capillaries; Vas-
cular disease; Vascular system 
BODY 
composition 
and growth hormone administration 
to hypopituitary dwarfs, 
•982-983 
and obesity and insulin secretion, 
•118 -
fat • ' 
and adipose tissue fat cell size and 
number, *180 
forearm metabolism 
and tolbutamide, •'1206 
growth ' .' 
and adrenocorticotropic , hormone 
unresponsiveness, *981f 
and Cushing's syndrome, *li.22 
and metabolic response to growth 
hormone, •119-120 
hands /.. • . 
and diabetic neuropathy, *314 
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height I 
and abetalipoproteinemia, *60 
height and weight 
in diabetes survey, 1193 
and muscle capillary basement mem-
brane changes, 883, 899-905 
limbs 
and gangrene surgery, ' • 187 
lower extrerriity ischemia 
and femorotibial bypass, *322-323 
organs 
and insulin and proinsulin degrada-
tion,. 1091-1100 
weight .}. * 
and adipose tissue glycerol kinase 
and lipolysis, *911-912 
and, diabetes, •362-363 
and hypothalamic damage, *1206 
and insulin sensitivity, 6-11 
and spontaneous diabetes in mon-
. keys, 1081 
weight reduction . 
cardiovascular effects of, *980 
and fat utilization and calorie restric-
tion, *835 
and insulin secretion, ° 1118 
BONE 
calcium, phosphorus, and magnesium 
and ' intestinal microflora, *775 
neonatal development , • :. ' 
and maternal protein restriction, 
•1047 
BOOK REVIEWS. 
Calories and Carbohydrates, by Bar-
bara Kraus, 908 
Current Topics on Glucagon, edited 
by M . Austoni, C. Scandellari, 
G. Federspil, and A. Trisotto, 
311 
Diabetic at Work and Play, The: A 
Modern Manual for Diabetics 
with the Latest Information 
on Oral Drugs, Diabetic 
Camps, Research and Many 
Other New Topics, by Buris 
R. Boshell, 908 
Gourmet Recipes for Diabetics: The 
International Diabetic Diet 
Book, by Dorothy Tompkins 
Revell, 908 
How to Live with Diabetes, by Henry 
Dolger,~and Bernard Seeman, 
1041 
BRAIN 
amino acid, amines and hexose up-
take, *315 
calcium 
and feeding response in satiated 
rats, *1046 
and extracellular markers for blood and 
cerebrospinal fluid transport, 
•774 
and galactose toxicity, *315 
glucose metabolism 
in newborn rat, *775 
hexokinase 
localization on synaptosomal mito-
chondria, *1205 
metabolism 
and galactose toxicity, 202-208 
and hepatic response to insulin-in-
duced hypoglycemia, 802-803 
and neonatal hypoglycemia, *910 
perfused rat 
glucose and D-3-hydroxybutyrate 
uptake, *1206 
perfusion technic, *1123 
utilization of ketone bodies 
and ketoacidosis, *247 
BRIJ 98 
and oral insulin, 643-647, 648 
BRUNNER'S GLAND 
enterokinase secretion 
and glucagon, *771 
BUPHENIN 
and hyperglycemia, °1045 
BUTYLAMINE 
and insulin secretion, *248 
CAFFEINE 
and cholesterol and. triglyceride 
changes during glucose toler-
ance tests 
in prediabetics, *365 
and insulin secretion, 540, 543, 571 
CALCIUM 
absorption 
and diabetes, °983 
binding mechanisms 
and hormones, •1121-1122 
and feeding response in satiated rats, 
•1046 
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and glucose ingestion in children, 
*376 
and insulin action, 696,697-698 
and insulin release, 544-545, 570, *837 
and insulin storage, 591-592 
intestinal absorption, *775 
in isolated adrenal cells, *982 
and lipoprotein lipase, *188 
and pancreatic beta cell amino acid 
uptake, *772 
and serum cholesterol and triglycerides 
and hyperlipidemia patients, *980 
uptake 
and cytochalasin B, 602, 605 
CALCIUM-45 
efflux from perfused islets, *326-327 
CALORIES 
intake 
and plasma insulin levels, 613, 617-
618 
and weight loss in obese hypergly-
cemic mice, *835 
and pregnancy 
and amino acid metabolism, •1118-
1119 
and maternal and amniotic fluid sub-
strate level, «1202 
CANDIDA ALBICANS ANTIGEN 
peripheral blood lymphocytes response 
to 
and diabetes, 906-907 
CAPILLARIES 
basement membrane thickening 
and age and diabetes, °837 
and pseudodiabetes of myopathy, 
•118 
muscle 
basement membrane changes, *254, 
881-896, 899-905 
permeability and blood flow 
and diabetes and prediabetes, *769 
and polyol pathway activity, *330 
CARBOHYDRATES 
antinatriuretic effects of, *772 
dietary 
and childhood ketotic hypoglycemia, 
•56 
and glucagon and insulin secretion, 
•912-913 
SUBJECT INDEX 1972 
and hypertriglyceridemia, *55 
and liver /glucoser6-phösphate dehy-
drogenase, 4$, 53 
and plasma tryptophan, *909 
and regulation ' of pancreatic en-
zymes, *186 
homeostasis' : \ 
and insulin, • glucagon and growth 
'hormone, *35,7 
and insulin release, 559-561 
metabolism » 
and adrenergic agents, * 1203 
arid age, •183-184 r 
arid alcohol, °247-248 
and catecholamines and methylpred-
" nisolone, •772 / 
and . diabetic microangiopathy, 872 
and glucagon, 939-944 
and glucose tolerance and insulin 
response to glucose, *I119 
in infants of diabetic mothers, *1046 
and menstrual; cycje, •1204 
and metformin, •914 
in newborn infants; of diabetic 
mothers,, *912; ' 
and psoriasis, • 2 5 0 / ' 
and streptozotocin, *59 
CARBOHYDRATE INTotfeRANCE 
and acromegaly, *352 
and chemical diabetes/screening in 
childhood, 46-47' 
severity of 
and proinsulin response to oral glu-
cose, •3j56 
CARBOHYDRATE TOLERANCE 
arid acute ^  uremia arid metabolic aci-
1 dosis/1109-1114 
and aging, *347/ 
and' progestin, *313 < • 
protein-bound*^ ; i !•/.'• 
; and diabetes, 803-870 i 
and serotonin, •1200 r 
CARBON DIOXIDE 
production .. ^ 
. : and obesity, 6-ljJ 
CARCINOMA l j ' 5 
arid glucose metabolism / ' 
• and insulin secretion/>* 1200 
islet'cell 1 l L u !; :; ; 
circulating insulin in, •909-910 
and streptozotocin therapy, • 1204 
and pancreatoduodenectomy, *188 
CARDIOVASCULAR DISEASE 
and disodium ethylenediaminetetra-ace-
tate and hypoglycemia, 960 
etiology, 679-680 
and oral hypoglycemic 5 drug labeling, 
, | , , ^ . ''*' f : 
and patient selection för UGDP, 1035-
1036. 
and pheochrompcytoma 
and insulin-dependent diabetes, *838 
CARDIOVASCULAR: SYSTEM 
in chickens 
and nonavian insulin, *59 
and weigrit reduction, *980 
CARNITINE V;;-. ^ ! : / " : ' : 
and liver ^älmitlate riietabolism, 259 
CASE REPORTS : 
abetalipoproteinemia, •ßO 
adipose tissue resection, 13-15 
adrenocorticotropic hormone unrespon-
siveness and excessive growth, 
... 0 981 
alcoholic ketoacidosis; ^56 
ateliotic dwarfism and growth hor-
mone treatment, *366 
concurrent bullous and atrophic skin 
i liesions, *251 
congenital neuroblastoma and islet 
:'v 1 hyperplasia, *1122 
Cushing's 'syndrome and growth re-
1 tardatiori, *1122 
diabetes 
• and defective pituitary reserve ca-
pacity, *981 
and hypokalemic nephropathy, 
•1042 A 
and mumps in siblings, *182 
in neonate, *249, 
and renal transplantation, *322 
and rhinocerebral / phycomycosis, 
• • • • * * 8 5 .. , / . 
secondary to. L-asparaginase ther-
apy in acute leukemia, •1119 
diabetic coma 
and fibrinolysis' and peritoneal dia-
lysis;. *913 , 
diabetic glomerulosclerosis without 
diabetes,' *769 
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stasis, •7 l71. , 
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and anti-insulin antibodies produc-
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nizattori, 814-825 , ; 
hyperparathyroidism' ' !! " i : '' 
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hypoglycemia during pregnancy follow-
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, *188•! • ' 
hypophysectomy during diabetic preg-
nancy, 972-974 
idiopathic hypoglycemia and epineph-
rine excretion, *1200 , 
infant hypoglycemia 
and cataracts, * 182 
infant ketoacidosis . 
new syndrome in, *18L 
insulitis and late-onset diabetes, 762-
763 _ t ; 9 
islet hypertrophy and b'eta-cell nyper-
plasia in juvenile 'diabetic, 
114-116 : ; 
ketoacidosis , and hemorrhaging, 108-
• HO • •/ ' • ' ' ' 
lipoatrophic diabetes without ketosis, 
827-830 
lipoatrophy, *381-382 ' " ' 
lipoproteitiemia, 745 
maternal blood sugar levels and'|fetal 
1 mortality 'and morbidity, 
•1201-1202 " Y 
pancreas transplantation, '355 
pheochromocytoma with insulin-de-
. pendent diabetes, *838 
temperate sprue, *773 
CATARACTS : 
and galactosemia, 202, 295-8Q0 , 
and infant hypoglycemia, *182 
and polyol accumulation., *352; > 
in tuco-tuco, *1206 
CATECHOLAMINES ^ 
action 
and cyclic AMP, *251 
blood glucose and: free, fatty acid re-
sponses to 
and noradrenaline and adrenaline, 
•912 
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and carbohydrate metabolism, *772 
and exercise-induced glucagon secre-
tion, *334 
and insulin secretion, *119, *316 
and methysergide, 783-784 
release 




and glucose intolerance, '*838 
CATS 
adrenalectohiized 
and splanchic nerve stimulation, 
•770 
CAUDAL DYSPLASIA 
and diabetic pregnancy, * 1042 
CEREBROSPINAL F L U I D 
and brain metabojism, *774 
and diabetic ketosis, *181 
CHICKS 
galactose toxicity in, *315 
and nonavian insulin 
and cardiovascular response, *59 
and oral glucose loading 
and plasma insulin and glucose, 
•1046 
ornithine utilization in, *771 
CHILDREN. See also Diabetes, juvenile; 
' Infants 
and chemical diabetes, 45-47 
and Cushing's syndrome 
, and1 growth retardation, * 11?2 
diabetes • control evaluation in, *361-
362 
and diabetic ketoacidosis: 
and coma, *60 
of diabetic parents 
retinal blood flow in, *354 
and effects of neonatal hypoglycemia, 
•910 
and glucose ingestion 
and calcium, magnesium and phos-
phorus flux, *376 
and glucose tolerance tests 
and diphenylhydantoin therapy, 
•355-356 
and growth hormone levels during 
sleep, *776 
and hypoglycemia, *248 
and epinephrine excretion, *1200 
and intravenous hyperalimentation, 
•837 
and ketotic hypoglycemia, *56 
obese 
and five-hour oral glucose tolerance 
test, *1042-1043 
and oral glucose tolerance tests, 16-20 
and salicylate-induced hypoglycemia, 
959 
of short stature 
and metabolic response to growth 
hormone, *119-120 
CHINESE 
and diabetes prevalence, °353 
CHINESE HAMSTER 
prediabetic 
diabetes prevention in, *337-338 
pancreas structure in newborns, 1051-
1059 
CHLORMADINONE ACETATE 
and insulin release, *313 
CHLORPROMAZINE 
-induced hypoglycemia, *184, 961 
CHLORPROPAMIDE 
antidiuretic action of, °189 




and Clofibrate, *838, *910 
levels 
and alloxan diabetes, 1163-1166 
and pediatric familial type I I hyper-
lipoproteinemia, °1043 
metabolism 
and Clofibrate, •1200-1201 
and insulin, *186 
and temperature, *314 
and metformin, *771 
CHOLESTEROL-C-14 
production 
and liver tissue injury; *315 
CHOLINERGIC AGENTS 
and pancreatic glucagon and insulin 
- secretion, *332 
CHORIONIC GONADOTROPIN 
and diabetic pregnancy, 33-34 
CHORIONIC SOMATOMAMMO-
TROPIN 
and insulin and glucagon release, 1072-
1075 
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and isolation of insulin-tryptophan 
complex, °1045 
and mucopolysaccharides assays, 735 
and glycoprotein study, 865-866 
and insulin antibodies study, 822-823 
and serum nonsuppressible insulin-like 
activity study, 271-278 
thin layer 
and sodium acetate incorporation 
into rat aorta lipids, 9186 
CHROMIUM 
dietary 
and diabetes in monkeys, 1079 
in glucose tolerance factor, *1043 
and glucose utilization 
and marasmus, *313 
hepatic 
and diabetes, *1046 
CINANSERIN 
and insulin secretion, 784-786 
CITRATE 
and amino acid metabolism, *56 
pancreatic 
and insulin release, 999-1001 
CITRIC ACID CYCLE 
and diabetic ketosis, 257 
and liver ketogenesis, 50-52 
CLOFIBRATE 
and cholesterol metabolism 
and hyperlipidemia, 01200-1201 
and fatty acid metabolism, *835 
and ischaemic heart disease, *838, *910 
and tumor-bearing mice, *837 
COLCHICINE 
and insulin release, 991, 996-997 
COLLAGEN 
in connective tissue study of diabetic 
rats, 736, 739 
COMA, DIABETIC 
and blood ketone body estimation 
method, •1117 
and blood lactic and pyruvic acids, 
•350 
and diabetic ketoacidosis, °60 
and drug-induced hypoglycemia, 955-
962 
and fibrinolysis and peritoneal dialysis, 
•913 
SUBJECT INDEX 1972 
and insulin, 632-633 
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binding to isolated white fat cells, 
•336-337 
and insulin, 1144 
CONGENITAL DEFECTS 
dwarfism, *368, 633, 872-873, *982-
983, °1046 
neuroblastoma and islet hyperplasia, 
•1122 
rubella 
and diabetes incidence, *248-249 
CORONARY DISEASE. See Arterio-
sclerosis; Cardiovascular dis-




and iodinated insulin, °55 
CORTISONE ACETATE 
and fasting triglyceride and cholesterol 
in offspring of diabetic couples, 
•1044-1045 
COXSACKIE B 4 VIRUS 
and diabetes, 766-767 
CTENOMYS TALARUM. See Tuco-Tuco 
CUSHING'S SYNDROME' 
and growth retardation, * 
in infancy, *120 
1122 
CYCLAMATES 
and blood constituents and hepatic 
lipids, *1202 
CYCLIC ADENOSINE ^ ^ ' - M O N O -
PHOSPHATE 
and adipose tissue metabolism • 
and insulin, 414-424 
and adrenalectomy, *340 
and amino acid metabolism, *56 
binding mechanisms, °1122 
formation 
in islet cell adenoma, *912 
formation and degradation 
in islet cell tumor, *185 
and glucagon 
and pancreatectomy, 453 
and glucose, 571 
arid glucose-induced insulin release, 
•1042 
and glucose release 
and glucagon, °332 
and glucose repression in rat liver, 
•187 
and glycogen synthase, 429, 433-436 
and growth hormone secretion, *313 
and hormone action, *251 
and insulin 
and lipolysis^ 403 
and liver metabolism, 439-445 
and insulin action, 454-455, 696-697, 
•772 . 
and insulin release, 1, 224-225, °312, 
•329, 545 
and prediabetes, 689-690 
in islet cell adenomas 
and glucose, glucagon, tolbutamide 
and theophylline, •346-347 
in isolated adrenal'cells, *983 
in isolated fat cells-, 1027-1034 
and amitriptyline, *1045 
and kidney gluconeogenesis, °910 
and lipolysis ... 
and mercury, ••771 r 
and tolbutamide, *836 
and liver protein synthesis, 453. -
and phosphofructokinase, °363 
and plasma insulin, *180 
and plasma insulin response to tolbuta-
mide; ° 311 
and protein synthesis; 
and hormones, *119 
in white fat cells • i. 
and tolbutamide, • 835 
CYCLIC ADENOSINE ^ ' - M O N O -
PHOSPHATE PHOSPHO-
DIESTERASE, 441, *838. 
and insulin, 415-416 
localization in islets of Langerhans, 
•328 
CYCLIC GUANOSINE ^ ^ ' - M O N O -
PHOSPHATE 
and glycogen synthase, 435 
phosphodiesterase activity against, 
•838 
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CYCLOHEXAMIDE 
and gluconeogenesis 
and glucocorticoid, *349 
and hexokinase, *185 
and insulin secretion, °55 
and rat adipocyte fatty acid synthetase 
activity, *914 
CYCLOHEXYLAMINE 
and insulin secretion, *248 
CYCLOPHOSPHAMIDE 
and immune response to insulin, *58 
CYPROHEPTADINE 
and acromegaly, *352 
and insulin release, 784-786 
and pancreatic beta-cell alterations, 71-
78 
CYTOCHALASIN B 




and shock, 0 1201 
2-DEOXYGLUCOSE 
and insulin release, 565 
in fetal rat pancreas, *121 
and insulin response to amino acids, 
1-5 
DEUTERIUM OXIDE 
and insulin release, 991-993, 996-997 
DEXTRAN 
-insulin complex 
and insulin action studies, *1122 
DEXTROSTIX 
and blood glucose determination, °119 
DIABETES MELLITUS 
and acute pancreatitis, °911 
and adipose tissue lipolysis, *36.1 
and adipose tissue resection, 13-15 
adult-onset 
and oral hypoglycemic agents and 
vascular complications, *57 
and 6-aminonicotinamide, 143-148 
and arterial calcification 
and glucose tolerance, *252 
in baboons, *338 
and bacteriuria, *118 
and beta-cell sensitivity to glucose, 
224-233 
and bladder dysfunction, °364 
and blood glucose levels 
and walking, 89-99 
and blood lymphocytes response to 
Phytohämagglutinin and Can-
dida albicans antigen, 906-
907 
and body weight constancy, *362-363 
and calcium absorption, *983 
chemical 
in children, 45-47 
and hyperglycemia and hyperinsulin-
' emia, *1121 
and circulating C-peptide immunoreac-
tivity, 1013-1025 
and connective tissue changes, 733-743 
control 
and diabetic retinopathy, *382 
diagnosis 
and glucose tolerance during preg-
nancy, *186 
and scintiphotoscanning, °351 
and UGDP patient selection criteria, 
1036 
duration 
and platelet aggregation, 0120-121 
and retinopathy, *187, *321-322 
and employment, 834-835 
etiology 
and insulin action, 698-700 
and viruses, 713-714 
and fructose, *314 
and gangrene surgery study, *187 
and glibenclamide therapy, *55, *913 
and glomerular lesions 
and proteinuria, °1120 
and glucagon, *60, *332 
and glucagon secretion, *183 
and gluconeogenesis 
and alanine, *341-342 
and glucose tolerance 
and microangiopathy, °321 
and glycoprotein fucose elevation, 863-
870 
and graded insulin infusions 
and plasma glucose, serum growth 
hormone and Cortisol re-
sponses to, °379 
growth-hormone induced 
and Huntington's chorea, 0374-375 
in guinea pigs, °338 
and hemochromatosis 
and angiopathy, °123 
hospital care for, °1120 
and Huntington's chorea, °1121 
and hyperphagia and polydipsia 
and adrenalectomy and hypophysec-
tomy, *358-359 
and hypertriglyceridemia 
and postheparin lipolytic activity, 
*342 
and hypophysectomy during preg-
nancy, 972-974 
and hypothyroidism, *769 
and impotence 
and androgenic function, 23-28 
incidence 
and congenital rubella, 0248-249 
and infection 
and plasma glucagon, *324 
and insulin 
and antigenicity, 649-656, 657-659, 
660 
and insulin antibodies, *57, *775 
insulin-dependent 
and acute hypoglycemic insulin ac-
tion, *182 
and blood glucose production and 
oxidation, *375 
and pheochromocytoma, *838 
and insulin disappearance rates, °1047 
and insulin and glucagon patterns, 
•359-360 
and insulin resistance 
and proinsulin antibodies, °368 
and insulin secretion, 608-613 
and alcohol hypoglycemia, 65-69 
and methysergide maleate, °315-316 
and xylitol and glucose, 0187-188 
insulin-treated, 632-636 
and plasma insulin, glucose and free 
fatty acids, °325 
and intestinal absorption, 0252-253 
and intestinal growth and hexose trans-
port in rats, °59 
juvenile 
and blood viscosity, *254 
control evaluation, *361-362 
and fructose, *349-350 
and glomerular basement membrane 
thickening, °913 
and growth hormone, *312 
and growth hormone metabolism, 
175-177 
and islet hypertrophy and beta-cell 
hyperplasia, 114-116 
and plasma lipid levels and diet, 
•366 
and programmed education, 967-971 
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and pseudo-dwarfism and Mauriac 
syndrome, 633 
"remission," 012O5 
and self-management, 012O4 
and sensory perception thresholds, 
01199 
and ketone body metabolism, *246 
and kidney disease 
in Pima Indians, *365-366 
late-onset 
and insulitis, 762-767 
-like syndrome 
and encephalomyocarditis virus in-
fection, *247 
and lipemia 
and insulin concentrations, 0376-377 
and liver cholesterol turnover, 0314 
and liver chromium content, 01O46 
and Oliver free fatty acid metabolism, 
* 280-288 
and Oliver gluconeogenesis 
and glucocorticoids, 0339-34O 
and liver 3-hypdroxybutyrate dehy-
drogenase, 0184-185 
and liver metabolism, 257-268 
and lower extremity ischemia 
and femorotibial bypass, 0322-323 
management, 683, 684 
computer-delivered protocol for, 
0367 
and diabetic neuropathy, 679 
and diet, 681-682 
and insulin, 678, 713 
and macroangiopathy and athero-
sclerosis, 679-680 
and microangiopathy, 680-681 
and new insulins, 637-647 
maternal 
and carbohydrate metabolism in 
newborn infants, *912 
and diabetic fetopathy, 687 
and infant erythroblastosis fetalis, 
*1199-2000 
and infant hypocalcemia, °914 
and infant hypoglycemia, 012O2-
1203 
and neonatal carbohydrate metab-
olism, *1046 
maturity-onset 
and diet, 1116-1117 
and serotonin antagonists, 0352 
and metabolic insulin clearance, 1003-
1011 
and metformin, 0 771 
and microangiopathy 
and age, 0837 
mortality studies, 01O44 
and mumps, 0182 
and muscle capillary basement mem-
brane changes, 881-896, 899-
905 
and muscle capillary permeability and 
blood flow, 0769 
in Mystromys albicaudatus, 715-721 
in neonate, 0249 
and neuropathy of hands, 0314 
new research on, 0314 
and obesity, 0246 
and insulin resistance, °370 
and insulin secretion, *1118 
and low calorie diet with phenter-
mine resin, *361 
and phenformin, 0362 
onset 
and heredity and diet, 077O 
and oral hypoglycemic drug labeling, 
833 
and pancreatic alpha cell function 
and insulin, 301-307 
and pancreatic beta cell function, 511 
and pancreas transplantation, °355 
and peripheral circulation 
infrared thermography studies, 0 981 
and phenformin 
and lactic acidosis, * 1198 
and pituitary gland reserve capacity, 
•981 
and placental glycogen metabolism, 
1185-1190 
and plasma amino acids, 0340-341 
and plasma glucagon levels, °324 
and plasma immunoreactive insulin 
during continuous blood glu-
cose monitoring, °324-325 
and platelet aggregation, *355 
and prediabetes transition to, 691-693 
prevalence 
among Florida Seminoles, 0776 
and heredity and obesity, *250 
prevention, 693 
and diet, *337-338 
and rat liver nuclear proteins, 0377 
and renal transplantation, 0322 
research 
and beta-cell dysfunction, 703-704 
and blood glucose analysis, 705-706 
and glucose-insulin relationships, 
704, 707-710 
and rhinocerebral phycomycosis, °185 
screening 
errors in, 0254 
and serum N-acetyl-beta-glucosamini-
dase, 1168-1171 
and serum phospholipids, 0123 
and serum protein changes 
and microangiopathy, *371 
and skin lesions, °251 
spontaneous 
in Macaca nigra, 1077-1088 
and submaxillary gland extirpation, 
722-731 
and sulfonylureas 
and kidney insufficiency, 01120-1121 
surveys 
among Chinese, 0353 
and Pima Indians, 018O 
of rural population of India, 1192-
1195 
therapy 
and U100 insulin, 832 
and thyrotoxicosis, 037O-371 
transient 
and L-asparaginase therapy in acute 
leukemia, 01119 
treatment 
and hemochromatosis, 01199 
and jet insulin injection, 39-44 
and sulfonylureas, 012O 
and UGDP, 1036-1037 
in tuco-tuco, 012O5 
unstable 
and biguanides, 0123 
and diurnal growth hormone and 
glucose abnormalities, 012O3 
and insulinogenic reserve, 0 836 
and vascular disease, °314 
and blood coagulation study, 108-
112 
in combined hyperlipoproteinemia, 
0376 
and venous changes, °909 
DIALYSIS 
and diabetes, 0 322 
peritoneal 
and diabetic coma, °913 
D I A M I N E OXIDASE 
and diabetic pregnancy, 35 
20, 25-DIAZACHOLESTEROL, 0837 
DIAZOXIDE 
and amino acid metabolism, 0 56 
and beta cell tumors, 535 
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and hyperresponsiveness to tolbuta-
mide, °360 
and insulin secretion, °327, 856-861, 
°1045 
and pancreatic beta cell uptake of 
amino acids, *772 
and tolbutamide response, *311 
DIBUTEROL 
and amino acid metabolism, °56 
DIBUTYRYL CYCLIC 3',5'-ADENO-
SINE MONOPHOSPHATE 
and fat cell metabolism, *343 
and insulin 
and adipose tissue lipolysis, 427 
and insulin release 
in acomys cahirinus, 1065, 1067 
and isolated fat cells, 1027-1034 
and lipolysis 
and insulin, 415-424 
and phosphofructokinase, *363 
and protein synthesis, *119 
D I E T 
and adipose tissue glucose metabolism 
and insulin response, 1152 
and alimentary lipemia, *58 
and blood constituents and hepatic lip-
ids, *1202 
and blood glucose control 
and tolbutamide and phenformin, 
976-978 
and blood glucose and serum insulin 
in obese hyperglycemic mice, *119 
carbohydrate 
and glucose metabolism, *179 
and pancreatic alpha cell function, 
301-307 
and cerebral development in rat fetus, 
•189 
and diabetes control, *361-362 
and diabetes management, 681-682 
and diabetes onset, *770 
and diabetes prevention, •337-338 
and diabetes survey of rural popula-
tion in India, 1192 
and diabetes treatment, 1116-1117 
diabetic 
and xylitol, *350-351 
and differential feeder for parabiotic 
rats, *983 
"elementar' liquids 
and hemolytic anemia and pancreatic 
acinar atrophy and fibrosis, 
•773-774 
and exocrine pancreas development in 
neonatal rat, *186 
food intake 
and stomach tumors in obese mice, 
•774 
galactose 
and motor nerve conduction studies 
in rats, 295-300 
and glucagon and insulin secretion, 
•912-913 
and glucose tolerance tests, 1197 
and growth hormone release during 
sleep, °913 
high fat 
and obese-hyperglycemic and non-
obese mice, *182 
high fructose 
and juvenile diabetes, *349-350 
high protein 
and liver gluconeogenesis from fruc-
tose and glycerol, *358 
and hyperlipemia 
in gerbils, *60 
and hypertriglyceridemia of streptozo-
tocin diabetes, 0 353-354 
-induced hypercholesterolemia, *1044 
-induced jejunal lipodystrophy, *248 
isocaloric 
in lipoproteinemia study, 744 
and konnyaku ingestion 
and serum insulin response to glu-
cose, *60 
and lactose intolerance, 871 
low calorie 
and anorectic agents, obese diabetics 
and, °361 
low casein and methionine 
and rat fatty liver metabolism, *183 
low cholesterol, high polyunsaturated 
fat 
and insulin sensitivity, °361-362 
and nutrient regulation of insulin se-
cretion, 606-615, 617-618 
and obesity 
and hyperinsulinemia, °249 
and pancreatic enzymes, *186 
in weaned rats, *59 
and pediatric familial type I I hyper-
lipoproteinemia, *1043 
and plasma glucagon, *331-332 
and plasma lipid levels, °366 
and proliferative diabetic retinopathy, 
•382 
protein-restricted 
and neonatal growth hormone pro-
duction and bone develop-
ment, *1047 
safflower oil 
and insulin secretion, 923-928 
sucrose 
serum triglyceride response to, *835 
and ventromedial hypothalamic nuclei 
destruction 
and glucose metabolism, * 1204-1205 
vitamin K deficient 
and resistance to oral anticoagulants, 
•183 
DIETHYLSTILBESTROL 
and insulin response to arginine and 
tolbutamide, °378 
DIHYDROXYACETONE 
and liver gluconeogenesis, 6330-331 
DI-ISOPROPYLAMMONIUM D I -
CHLORACETATE, °358 
D I L A N T I N . See Diphenylhydantoin 
DIMETHYLBIGUANIDE. See Met-
formin 
DIPA. See Di-isopropylammonium di-
chloracetate 
DIPHENYLHYDANTOIN 
and alloxan diabetogenic action, 80-83 
and insulin secretion, *327, 856-861, 
•982 
long-term therapy 
and glucose and insulin responses to 





and hypoglycemia, 960 
DIURESIS 




in progeny of protein-deficient rats, 
•1041 
in mouse diaphragm, *184 
pancreatic 
and diet in neonatal rats, *186 
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DOGS 
and acute uremia and metabolic 
acidosis 
and carbohydrate tolerance, 1109-
1114 
adrenalectomized 
and splanchic nerve stimulation, 
*770 
and ammonium chloride acidosis 
and glucose tolerance, 794, 796 
and antidiuretic action of chlorpropa-
mide, *189 
arginine and tolbutamide infusion 
and diethylstilbestrol and growth 
hormone, *378 
Brunners gland secretion in 
and glucagon, *771 
and carbohydrate metabolism 
and catecholamines and methyl-
prednisolone, *772 
depancreatized 
and discovery of insulin, 385-394 
glucose turnover rates during Rin-
ning, *382-383 
and exercise 
and plasma glucagon, * 1198-1199 
and glucagon secretion 
and growth hormone, *313 
glucagon studies in, *360-361 
and glucose feeding 
and insulin secretion, *911 
and glucose kinetics studies, *188 
hypophysectomized 
and tolbutamide and glybenclamide 
injections, *378-379 
and insulin antibodies, *182 
insulin distribution and binding in 
hindlimb of, *775 
and insulin-induced hypoglycemia, 802-
803 
and insulin release 
and amino acids, °56 
and insulin secretion 
and oral glucose feedings, *909 
and thyroxine and hypophysectomy, 
°253 
and intestinal glucagon-like immuno-
reactivity 
and insulin secretion and glucose 
levels, *58 
liver free fatty acids metabolism 
and anti-insulin serum, 280-288 
mongrel and beagle 
and senim insulin response, °356 
and pancreas blood flow and insulin 
output 
and prostaglandins, *369 
partially depancreatized 
and glucose tolerance and insulin 
response, °339 
and pepsin secretion study, °250 
reticuloendothelial system 
and vascular clearance and lipid 
metabolism, °312 
and secretin 
and diuresis, *769 
and sodium linoleate infusion 
and plasma free fatty acids, glu-
cose, insulin and ketones, 
1179-1184 
submaxillary gland extirpation in 
and glucose and insulin tolerance, 
722-731 
and tolbutamide response 
and diazoxide, *311 
L-DOPA 
and plasma free fatty acids and glu-
cose, *1121 
and plasma growth hormone, insulin, 
and thyroxine, *911 
DOPAMINE 
and insulin secretion, *184 
-sensitive adenyl cyclase 
and synaptic transmission, °773 
DOPAMINE BLOCKING AGENTS 
and insulin release, 783-784 
D. PNEUMONIAE 
and liver cycloleucine, *316 
DULCITOL 
and nerve conduction defect in galac-
tose-fed rats, 295-300 
DWARFISM 
ateliotic 
and growth hormone treatment ef-
fect on glucose tolerance and 
adipose tissue cellularity, 
*366 
and plasma insulin response to glu-
cose, * 1045-1046 
diabetic sexual ateliotic 
and microangiopathy, 872-873 
hypopituitary 







and diabetic ketosis, *180-181 
ELECTROPHORESIS 
agar, 816 
of glycoproteins and collagen 
in connective tissue study of dia-
betic rats, 736, 738-739 
and neutral regular insulin study, 236, 
241 
ELIPTEN, *837 
EMBRYO, See also Fetus 
pancreas islets study, 511-533 
EMIOCYTOSIS 
and insulin release, 535, 603 
ENCEPHALOMYOCARDITIS VIRUS 
and diabetes-like syndrome, °247 
and mouse pancreas, °338-339 
ENDOCRINE GLANDS 
adenomatosis 
and familial nesidioblastosis, *1122 
and diabetic microangiopathy, 872-873 
ENDOPEPTIDASE 
trypsin-like 




and diabetes, 1168-1171 
adenyl cyclase 
and nervous system function, *773 
adenyl cyclase and cyclic AMP phos-
phodiesterase 
localization in rat islets of Langer-
hans, *328 
adenylate cyclase and phosphodiester-
ase 
and insulin release, *328-329 
aldose reductase 
and insulin release, *327 
assays 
and diabetic pregnancy, 34-35 
and cyclic AMP 
and insulin,. 439-445 
cyclic AMP phosphodiesterase, *328 
and insulin, 415-416 
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enterokinase 
and glucagon, *771 




and insulin, 428-437 
glycogen synthetase and Phosphorylase 
and diabetes, 1185-1190 
glycolytic 
and insulinoma, *773 
hexokinase, °1205 
and insulin degradation, 468 
by placenta, *374-375 
and proinsulin assays, *122 
and insulin and proinsulin degradation, 
1093-1100 
in jejunal mucosa 
and alloxan diabetes and fasting in 
rats, *188 
lipoprotein lipase 
in rat heart and adipose tissue, *344 
liver 
and alcoholism, *983 
liver acetic thiokinase 
and lipogenesis, °982 
liver adenylate cyclase 
and glucagon, *981 
liver threonine dehydratase, *980-981 
pancreatic 
and diet, *186 
and serum anti-insulin, *911 
phosphodiesterase 
and cyclic AMP and cyclic GMP, 
*838 
phosphofructokinase 
and cyclic AMP and dibutyryl cyclic 
AMP, *363 
of placental polyol pathway, *330 
and proinsulin conversion to insulin, 
577-578, 581-583 
proteolytic 
and fat cell lipolysis, 423 
and leucine incorporation into pro-
tein, *336 
EPINEPHRINE 
adenyl cyclase response to, *772 
and calcium transport, *327 
and cyclic AMP, 441, 445 
excretion 
and idiopathic hypoglycemia, *1200 
and glucagon secretion, *332-333 
and glycogen synthase, 436 
and insulin 
and adipose tissue lipolysis, 427 
and insulin release 
and glucose administration, *348 
and insulin response to glucose, *773 
and insulin secretion, *770 
and lipolysis 
and mercury, *771 
and protein synthesis 
and cyclic AMP, *119 
-responsive adenyl cyclase 
and insulin, * 1117-1118 
-stimulated lipolysis 
in siblings of diabetics, *361 
ERYTHROBLASTOSIS FETALIS 
and fetal pancreas, *253-254 
and glucose metabolism, plasma insu-
lin and growth hormone se-
cretion, * 1199-2000 
17B-ESTRADIOL 
and tRNA methylases, *253 
ESTROGEN 
and diabetic pregnancy, 31-32 




and gluconeogenesis, °1202 
blood clearance of 
and alcoholism, *983 
and diabetes, *1042 
-induced fatty liver 
and pyrazole and glucose, *247 
-induced hypoglycemia, 958 
and insulin release 
in healthy subjects, 158-161 
and intestinal triglyceride synthesis, 
•769-770 
metabolism 
and hypo-, hyper, and euthyroid 
rats, °181 
and muscle damage, *838 
and phenformin 
in obesity and prediabetes, °363 
and skeletal muscle lactate metab-
olism, *367 
ETHINONINE 
and pancreas mitotic activity, 1055 
EXERCISE 
and amino acid levels 
in fasted and fed rats, *119 
and amino acid metabolism, *770-771 
and cardiovascular system 
and weight reduction, *980 
decreased 
and glucose intolerance, 101-107 
and glucagon secretion, * 1198-1199 
and glucose metabolism, *179, *776 
and glucose turnover in depancreatized 
dogs 
and insulin and glucagon infusion, 
°382-383 
-induced glucagon secretion 
and catecholamines, *334 
and insulin and glucose uptake, *980 
and insulin secretion 
and obesity, *909 
and phentolamine, *119 
and lactic acid levels 
and phenformin and Tolinase therapy, 
°351 
walking 
and blood glucose levels in normals 
and diabetics, 89-99 
F 
FAMILY HISTORY 
and alcohol-induced glucose intoler-
ance, *184 
and chemical diabetes in children, 45 
and diabetes following mumps in sib-
lings, *182 
and diabetes prevention, *337-338 
and endocrine adenomatosis, *1122 
and epinephrine-stimulated lipolysis, 
*361 
and mytotonic dystrophy 
and insulin secretion, °378 
and prediabetes, *359 
and renal glycosuria, °248 
and sensory perception thresholds in 
relatives of diabetics, °1199 
FASTING. See Starvation 
FAT CELLS. See also Adipose tissue 
adenylate cyclase 
and insulin, °772 
and antilipolytic action of tolbutamide, 
*836 
and insulin action study, 454 
insulin binding with membranes of, 
398-401 
and insulin and lipolytic hormones 
and mercury, *771 
insulin receptor of 
and insulin resistance, *1042 
leucine incorporation into protein by, 
°336 




April , 193-256 
May, 257-320 
Supplement 1, 321-384 









SUBJECT INDEX 1972 
lipolysis 
and insulin, 414-424 
lipolysis and cyclic AMP 
and aniitriptyline, *1045 
and tolbutamide, °835 
metabolism 
and dibutyryl cyclic AMP, *343 
and insulin, *351-352, 403-411 
purification of plasma membranes 
and adenyl cyclase response to hor-
mones, *772 
and receptor sites for insulin and cyc-
lic nucleotides, °336 
size and number 
assay method, °247 
and enlargement of epididymal fat 
pads, *247 
white 
concanacalin A binding to, *336-337 
FATS 
and insulin release, 613-615, 617-618 
tolerance 
and oral contraceptives, °316 
FATTY ACIDS 
free 
and anti-insulin serum, 280-288 
and glucagon, *60 
and glucose ingestion, 1104-1105 
and /3-hydroxybutyrate, *836 
and hypertriglyceridemia and phen-
formin, *380 
and phenformin, °1045 
release from adipose tissue, °59-60 
renal, *314 
responses to catecholamines, adren-
aline and noradrenaline and, 
*912 
and streptozotocin, *59 
and insulin release, 613-615, 617-618 
metabolism 
and pancreas alpha and beta cells, 
°909 
by sheep liver and viscera, *118 
and thrombin, *312 
oxidation, oxidative phosphorylation 
and diabetic rat liver mitochondria 
ultrastructure, 257-268 
release by adipose tissue 
and insulin, 414-424 
synthetase activity 
and glucose and insulin, *914 
FETUS 
cerebral development 
and diet and growth hormone 
studies, *189 
and diabetic fetopathy, 687 
endocrine pancreas 
cytological studies, *253-254 
fibroblasts 
glucose oxidation in, *360 
growth 
and maternal diabetes, *912 
insulin response 
and arginine, *251 
lamb 
and metabolism studies, *187 
and maternal diabetes, 31, *315, 687, 
*912 
mortality 
and diabetic pregnancy, 31 
mortality and morbidity 
and maternal blood sugar levels, 
*1201-1202 
pancreas, 620, 621, 623-624 
insulin content, 193-201 
insulin release studies, 0345-346 
islets study, 511-533, 536 
and placental nitrogen conservation, 
°340 
and streptozotocin therapy, *316 
subhuman primate 
and theophylline, *180 
FIBRINOLYSIS 
and diabetic coma, °913 
FIBROBLASTS 
cultured 
glucose oxidation in, *360 
of granulation tissue 
and antismooth muscle serum, *314 
F L U I D SECRETION STUDIES, *315 
FLUPHENAZINE 
-induced hyperglycemia, *184 
FOOD AND DRUG ADMINISTRATION 
and labeling of oral hypoglycemic 
drugs, 833, 1116-1117 
FORMALDEHYDE 
-treated insulin, °55 
FREEZE ETCHING TECHNIC, *326, 
619-620 
FRUCTOSE 
and diabetes, *314 
dietary 
and diabetic children, °349-350 
and fetal metabolism, *187 
gluconeogenesis from, *358 
and insulin secretion, 543, 561 
and liver glucose production 
and insulin-induced hypoglycemia, 
797-803 
metabolism 
in fasted and streptozotocin diabetic 
rat, *122 
in nervous tissues 
and blood sugar control, 1173-1178 
serum triglycerides response to 
and age, *835 
small intestine permeability for, *249 
D-FRUCTOSE 
and insulin response to glucose, 540 
transport 
and biguanides, *119 
FUCOSE 
protein-bound 
and diabetes, 863-870 
G 
GALACTOSE 
and insulin release, 543, 561 
and nervous system defects, 295-300 
toxicity, °315 
and brain metabolism, 202, 208 
D-GALACTOSE 
and alloxan toxicity, *123 
and insulin response to glucose, 540 
intestinal uptake, *249 
transport 
and biguanides, *119 
GALACTOSEMIA 
and brain metabolism, 202, 208 
and diabetic microangiopathy, *352 
GAMMA GLOBULIN 
and insulin complexes 
and diabetic microangiopathy, 872-
879 
GANGRENE 
and femorotibial bypass, °322-323 
and insulin response, *836 
and limb salvage arterial surgery, °187 
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GASTRECTOMY 
and glucagon and insulin response, 
•1047 
GASTRIN 
and insulin secretion, 535 
GASTROENTERITIS 
and hypoglycemia, °248 
GASTROINTESTINAL SYSTEM 
absorption 
and diabetes, *252-253 
and cholecystokinin 
and secretin, °252 
and diet-induced jejunal lipodystrophy, 
°248 
diseases 
and "elemental liquid" diets, *773-
774 
and duodenal acidification 
and pepsin secretion study, *250 
enzyme activity 
in rats, *59 
gastric emptying rate 
and oral glucose tolerance tests, °381 




and insulin and glucose, *58 
glucose and galactose absorption, 1107 
growth and hexose transport 
in diabetic rats, *59 
hormones 
and insulin response to triglyceride, 
928 
and insulin administration 
and plasma immunoreactive insulin, 
203-207 
jejunal mucosa 
and glycolytic and pentose phosphate 
pathway enzymes, *188 
lipodystrophy 
diet-induced, °1044 
lipoprotein production, *121 
mechanical stimulation of 
and serum insulin response to glu-
cose, *60 
microflora 
and calcium and magnesium absorp-
tion, °775 
and oral insulin, 643-647 
permeability to glucose 
and synthetic surfactants, * 182-183 
and portacaval shunting 




and insulin response to glucose ab-
sorbed from, *54 
small intestine 
permeability for fructose, °249 
sugar transport 
and biguanides, *119 
surgery 
and glucose homeostasis, °1199 
transport 
and glucagon, *983 
triglyceride synthesis 
and ethanol, *769-770 
xylitol absorption, *350-351 
GEESE 
and liver metabolism 
and glucagon, *55 
GENES 
and autosomal recessive inheritance of 
renal glycosuria, *248 
and familial hypercholesterolemia, 
°1121 
and longevity in mice, *914 
GERBILS 
and diet-induced intestinal lipodys-
trophy, *1044 
and hyperlipemia, *60 
pancreas structure in newborns, 1051-
1059 
GIRAFFES 
muscle capillaries basement mem-
brane width in, "254 
GLIBENCLAMIDE 
and amino acid metabolism, *56 
-glucose-response-test, *913 
intrapancreatic infusion 
and insulin release, 209-215 
and pancreatic beta cell uptake of 
amino acids, °772 




pharmacodynamic aspects, *249, *249-
250 
GLICLAZIDE 
and microangiopathy, *357 
GLISOXEPIDE 
pharmacodynamic aspects, *249, *249-
250, *912 
GLOMERULOSCLEROSIS, DIABETIC 
immunohistopathological study of, 163-
173 
without diabetes, °769 
GLUCAGON 
action 
and cyclic AMP, °251 
and adenosine 3'5'-monophosphate 
levels, *54 
and adenyl cyclase activation in islet 
cell adenoma, *912 
adenyl cyclase response to, *772 
biosynthesis, *58-59 
and carbohydrate homeostasis, °357 
and carbohydrate metabolism, insulin 
and growth hormone secre-
tion 
in congestive heart failure patients, 
939-944 
chronic administration of 
and glucose tolerance and insulin 
hyperresponsiveness, *374 
and cyclic AMP, 440 
and pancreatectomy, 453 
and diabetes 
and infection, *324 
and diuresis, °769 
and enterokinase secretion, *771 
gastrointestinal response to, *1047 
and gastrointestinal transport, *983 
and gluconeogenesis, *331 
and hypoglycemic coma, 961-962 
immunoreactive 
in islet cell tumors, *333 
and immunoreactive insulin 
and blood glucose, *360-361 
infusion 
and glucose turnover in depancre-
atized dogs, ° 382-383 
and insulin immunoreactivity, *313 
-insulin ratio 
and liver metabolism, °341 
and insulin release 
and arginine, *312 
and insulin response, 1 
in acomys cahirinus, 1064, 1069 
and islet cell adenoma cyclic AMP con-
tent, °346-347 
kidney sensitivity to 
and starvation, *334 
-like immunoreactivity 
assays, *1206 
and insulin secretion and glucose 
concentration, *58 
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and liver adenosine 3',5'-monophos-
phate and glucose, °187 
and liver cirrhosis, * 121-122 
and liver gluconeogenesis 
and D-glyceraldehyde and dihy-
droxyacetone, *330-331 
-mediated plasma insulin responses 
and theophylline, °180 
metabolism, *333 
and diabetes, °332 
and myocardial oxygen consumption 
and potassium balance, °118-
119 
physiology and pathophysiology, *60 
and plasma amino acids, *340-341 
and plasma lipids and blood platelets, 
°311-312 
and related synthetic peptides, 843-
855 
release 
and human chorionic somatomamm-
otropin, 1072-1075 
resistance 
and lipemia, *357 
-responsive adenyl cyclase 
macromolecular inhibitor of, °180 
secretion, *314 
adrenergic control of, *332-333 
and alanine, *183 
and aminophylline, 289-293 
and catecholamines, *334 
and diet, *912-913 
and exercise, *1198-1199 
during glucose infusions in starva-
tion and diabetes, *359 
and growth hormone, °313 
and insulin deficiency, *183 
and pituitary and adrenal glands, 
°375 
selectively blocked 
and liver adenylate cyclase, °981 
scrum insulin response to 
in mongrel and beagle dogs, °356 
GLUCAGON 1-131 
and glucagon metabolism studies, *333 
GLUCOCORTICOIDS 
and ACTH, growth hormone or thy-
roxine and ketosis, 414 
and diabetic ketosis, 946-954 
and gluconeogenesis, *252 
and liver gluconeogenesis 
and diabetes, *339-340 
and liver mitochondrial structure, 258 
GLUCONEOGENESIS 
and alanine 
and diabetes, °341-342 
and ethanol, °1202 
from arginine, 308-310 
and cyclic AMP 
and insulin, 439-445 
from fructose and glycerol 
in liver of high-protein fed rats, *358 
and glucagon, °183 
and glucocorticoids, °252 
GLUCORECEPTOR MECHANISMS, 
555-568, 570, 611-613 
GLUCOSAMINE 
and insulin release, °328, 543, 544, 
561, 570 
D-GLUCOSAMINE 
and insulin response to glucose, 540-
541 
GLUCOSE. See also Glucose intolerance; 
Glucose tolerance; Glucose 
tolerance tests 
absorption 
and gut glucagon-like immunoreac-
tivity, *837-838 
absorption from small bowel 
and insulin response, *54 
and adenyl cyclase activity, *179 
and alloxan 
and insulin secretion, °326 
and alloxan toxicity, *123 
and amino acid metabolism, °56 
and arginine 
and serum insulin and growth hor-
mone, °316 
beta cell sensitivity to 
and prediabetes and diabetes, 224-
233 
binding to intestinal epithelial brush 
borders 
and diabetes, *252-253 
brain metabolism 
in newborn rat, °775 
and calcium metabolism, *327 
disappearance rates 
in infants of diabetic mothers, *1046 
and methysergide maleate, *316 
disposal 
and myopathy, *118 
and ethanol-induced fatty liver, *247 
and fatty acid metabolism, *835 
and fatty acid synthetase activity, *914 
and fetal metabolism, °187 
glibenclamide-response-test, °913 
and glucagon, *60 
and glucagon-like immunoreactivity, 
°58 
homeostasis 
and gastric surgery, °1199 
and glucagon, *314 
and hypoglycemia, 815 
and hypoglycemic coma, 961 
infusion 
insulin and glucagon patterns dur-
ing, *359-360 
ingestion 
and metabolism, 1102-1108 
ingestion in children 
and calcium, magnesium and phos-
phorus flux, °376 
and insulin 
and hypoglycemia, °373 
and lipoatrophy, * 381-382 
-insulin relationships, 704, 707-710 
and insulin secretion, *55, 143, 157-
161, *370, 606-613, 617-618, 
713, 989 
in acomys cahirinus, 1062 
and adenylate cyclase and phos-
phodiesterase, °328-329 
and ammonium ion, *248 
and arginine, °312, *1045 
and carbohydrate and lipid metab-
olism, *1119 
and Chlormadinone acetate, *313 
and cyclic AMP, *1042 
and cytochalasin B., *327 
and diabetes and obesity, * 187-188 
and diphenylhydantoin and diazox-
ide, 856-861 
and epinephrine, *770, *773 
and human chorionic somatomam-
motropin, 1072-1075 
and immunohistological detection of 
insulin in pancreatic tissue, 
»246 
and iodoacetate and antimycin A, 
*56 
and juvenile diabetes "remission," 
M205 
and konnyaku ingestion, *60 
and kwashiorkor, *1119-1120 
and methysergide, 780-787 
and ouabain, *246 
and peripheral vascular disease, ar-
teritis, and Raynaud's phe-
nomenon, *836-837 
in rat islets, *1205 
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and serotonin and dopamine, »184 
and small vessel disease, »836 
stimulus-secretion coupling of, 594-
603 
and tolbutamide, 684 
intestinal permeability to 
and synthetic surfactants, »182-183 
intestinal transport 
and biguanides, »119 
and islet cell adenoma cyclic AMP 
content, »346-347 
kinetics 
in dogs, »188 
levels 
and alcohol hypoglycemia, 65-69 
and liver cirrhosis and insulinemia, 
»121-122 
and liver gluconeogenesis, »371 
loading 
and diet and fasting, »1046 
and iodinated insulin, »55 
and obesity, »54 
and maternal diabetes 
and infant hypoglycemia, »1202-
1203 
metabolism 
adipose tissue, 1151-1161 
and carcinoid syndrome, »1200 
and cyclic and dibutyryl AMP, 
1028-1030 
and erythroblastosis fetalis, »1199-
2000 
and insulin, »184 
in isolated pancreas islets, 538-545 
in isoproterenol-stimulated rat sal-
ivary glands, »982 
during leg exercise, »776 
and methylene blue, »350 
and obesity, 6-11 
and pancreas alpha and beta cells, 
»909 
in rat skin, »189 
and shock, »1201 
and ventromedial hypothalamic nu-
clei destruction, »1204-1205 
oral 
and alimentary lipemia, »58 
and insulin secretion, »909, »911 
output 
and insulin and adenosine 3',5'-
monophosphate, »254 
oxidation 
in cultured fibroblasts, »360 
and exercise and dietary carbohy-
drate, »179 
of isolated islets in tissue culture, 
548, 550-551 
and norepinephrine and theophylline, 
416-417 
pancreatic islet response to, »344-345 
and plasma glucagon, growth hormone 
and insulin 
during exchange transfusion, »1120 
and plasma insulin 
and diabetes, 1012 
and theophylline, »180 
and plasma and pancreatic insulin, 
»375-376 
production 
and mannose, fructose and hydroxy-
butyrate, 797-803 
proinsulin response to 
and age, obesity, and degree of car-
bohydrate intolerance, »356 
prolonged infusion 
and insulin secretion, »372 
regulation 
and hypertension, »776 
renal, »314 
repression in rat liver 
cyclic 3'5'-AMP during, »187 
responses 
and diphenylhydantoin therapy, 
»355-356 
and serum insulin levels 
and trauma, »183 
-stimulated insulin release 
and glucoreceptor mechanisms in 
islets of Langerhans, 555-568 
and insulin storage, 585-592 
and sulfonylureas, »249-250 
transport 
in fat cells, 403 
in rat adipose tissue, »1042 
turnover 
in depancreatized dogs, »382-383 
uptake 
and exercise, »980 
by isolated perfused rat brain, »1206 
uptake by brain 
and perfusion technics, »1123 
uptake by fat tissue 
and 0-hydroxybutyrate, »836 
utilization 
and chromium, »313 
and growth hormone, »342-343 
and thyrotoxicosis, »370-371 
GLUCOSE INTOLERANCE 
alcohol-induced, »184 
and catecholamine-secreting tumors, 
»838 
and chromium deficiency, »313 
and decreased physical activity, 101-107 
and gastrectomy, »1047 
and hypokalemia, »1043-1044 
and myocardial infarction, »119 
and obesity, »1118 
and phenytoin, »187 
GLUCOSE TOLERANCE 
and acute uremia and metabolic aci-
dosis, 1109-1114 
and alcohol, »247-248 
and ammonium chloride-induced aci-
dosis, 794-796 
and arterial calcification, »252 
and carbohydrate and lipid metab-
olism, »1119 
and chronic glucagon administration, 
»374 
and encephalomyocarditis infection, 
»247 
and glibenclamide, »55 
and growth hormone treatment 
in ateliotic dwarfism, »366 
and insulin response 
in partially pancreatized dogs, »339 
intravenous 
and myocardial infarction, »184 
and metformin, »771 
and microangiopathy, »321 
and myotonic dystrophy, »378 
and nicotinic acid, »313 
and obesity, 759, »1205 
and portacaval shunt in rats, »179 
and prediabetes, 686 
and renal lesions, »769 
seasonal variations in, »312-313 
and submaxillary gland extirpation, 
722-731 
and temperate sprue, »773 
GLUCOSE TOLERANCE FACTOR 
and insulin, »1043 
GLUCOSE TOLERANCE TESTS 
and acute pancreatitis, »911 
and bedrest and exercise, 102-106 
and caffeine 
and prediabetes, »365 
and chemical diabetes in childhood, 
46-47 
and Chinese, »353 
in diabetics and obese patients, 1012 
and diphenylhydantoin therapy, »353-
356 
and ethanol and phenformin, »363 
among Florida Seminoles, »776 
and gastric emptying, »381 
and glucose metabolism, 1102 
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in guinea pigs, »338 
and Huntington's chorea, »1121 
and hypertension, »776 
and liver cirrhosis, »356 
in Macaca nigra, 1078-1088 
and myocardial infarction, »119 
in neonates of diabetic mothers, »912 
in obese children, 61042-1043 
and obesity, »1205 
oral 
and diabetes screening errors, °254 
discriminant analytical technic, »251 
and serum insulin and growth hor-
mone levels in children, 16-20 
standardization of, 1197-1198 
and peripheral vascular disease, ar-
teritis, and Raynaud's phe-
nomenon, »837 
and phenformin 
and diabetic obesity, »362 
and Pima Indians, »180 
plasma catecholamines during, »348 
and plasma insulin and uric acid 
and nicotinic acid, »313 
and plasma lipids 
in normals and prediabetics, »383 
and pregnancy, »186 
and serum immunoreactive insulin 
levels and age, »183-184 
D-GLUCOSE 
and alloxan toxicity, »123 
brain uptake of 
and phlorizin, »315 
and insulin release, 559-561 
transport 
and biguanides, »119 
GLUCOSE C-14 
metabolism 
and 6-aminonicotinamide, »1198 
GLUCOSE-6-PHOSPIIATE DEHY-
DROGENASE 
in jejunal mucosa 
and alloxan diabetes, »188 
GLUCOSE U-C-14 
metabolism 
in fasted and streptozotocin diabetic 
rats, »122 
utilization 
rat strain differences in, »770 
GLUCOSURIA 
and chemical diabetes screening, 47 
and dietary fructose, 4349 









and hvpophysectomized dogs, »378-
379 
GLYBURIDE. See Glibenclamide 
D-GLYCERALDEHYDE 
and liver gluconeogenesis, »330-331 
GLYCERIDE-GLYCEROL SYNTHESIS 
of mammalian adipose tissue, 1154-
1155 
GLYCEROL 
gluconeogenesis from, »358 
and insulin secretion, 923-928 
release 
and weight reduction, 758 
GLYCEROL KINASE 
in adipose tissue 
and body weight, »911-912 
and insulin regulation, »122 
L-GLYCEROL 3-PHOSPHATE 





and diabetes, 1185-1190 
GLYCOGEN STORAGE DISEASE 
and hypoglycemia, »248 
GLYCOGEN SYNTHASE 
and insulin, 428-437 
GLYCOGENOLYSIS 
and arginine infusion, 308-310 
and cyclic AMP 
and insulin, 439-445 
GLYCOLATE 
urinary 
and streptozotocin diabetes, »372 
GLYCOLYSIS 
and insulin secretion, 4 
GLYCOPROTEIN 
in connective tissue study of diabetic 
rats, 736, 738-739, 740-741 
GLYCOPROTEIN FUCOSE 
and diabetes, 863-870 
GLYCOSAMINOGLYCANS 
metabolism 
and alloxan diabetes, 1162-1166 
GLYCOSURIA 
and diabetes prevalence among Chi-
nese, »353 
in diabetes survey of rural population 
in India, 1193-1196 
and insulin, »186 
and nicotinic acid, »313 
GOLGI APPARATUS, 620 
and insulin biosynthesis, 574-577, 582, 
583 
and insulin secretion, 510 
GROWTH HORMONE 
activity 
and lipoatrophy, »381-382 
and body composition of hypopituitary 
dwarfs, »982-983 
and carbohydrate homeostasis, »357 
and cerebral development in rat fetus, 
»189 
and diabetes, 699-700, »1203 
and diabetic ketosis, 946-954 
and diabetic retinopathy, »349 
diurnal 
ami unstable diabetes, »1203 
and glucagon secretion, »313 
and glucose tolerance and adipose tissue 
cellularity 
in ateliotic dwarfs, »366 
homeostasis abnormalities 
and generalized lipodystrophy, »771 
-induced diabetes 
and Huntington's chorea, »374-375 
insufficiency 
beta-1-24 corticotropin tests of, »775-
776 
and insulin response to arginine and 
tolbutamide, »378 
and juvenile diabetes, »312 
levels 
in small normoglycemic and hypo-
glycemic infants, »250 
and lipid and carbohydrate homeo-
stasis, »342-343 
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and lipoatrophic diabetes, 829, 830 
and lipolysis 
and iodinated insulin, »55 
metabolic clearance rates 
and juvenile diabetes, 175-177 
metabolic response to 
and short stature, * 119-120 
and metabolism of obese patients, »1046 
neonatal 
and maternal protein restriction, 
»1047 
and pancreas compartments of insulin, 
»372 
release 
in sleep, »776, »913 
secretion 
and Cushing's syndrome, °1122 
and L-dopa, »911 
and erythroblastosis fetalis, »1199-
2000 
and glucagon, in congestive heart fail-
ure patients, 939-944 
and prostaglandins, »313 
regulation by growth hormone, 22, 
30 
and serum secretin, »1118 
sex-based variation of, *774-775 
synthesis 
and lipids, »187 
GUINEA PIGS 
adipose tissue 
glucose metabolism and insulin re-
sponse, 1151-1161 
and diabetes, »338 
immune response to insulin, »58 
perfused liver 




and hypoglycemia, 960 
and insulin secretion, 783-784 
HAMSTERS. See also Chinese hamsters; 
Mystromys albicaudatus 
adipose tissue 
glucose metabolism and insulin re-
sponse, 1151-1161 
and insulin secretion 
and glucose and tolbutamide, »370 
and islet cell tumors 
and cyclic 3'5' AMP, »185 
and insulin studies, »313 
HEART 
myocardial oxygen consumption and 
potassium balance 
and glucagon, »118-119 
perfused rat 
and lipoprotein lipase release, 149-
155 
rat 
lipoprotein lipase, »344 
rat aorta 
and sodium acetate incorporation, 
»186 
HEART DISEASE. See also Arterioscler-
osis; Myocardial infarction 
congestive heart failure 
and glucagon infusion, 939-944 
ischaemic 
and Clofibrate, »838, »910 
HEMOCHROMATOSIS 
and diabetes, »1199 
and diabetic angiopathy, »123 
HEMORRHAGE 
and argon laser photocoagulation, »189 
and diabetes, 108-112 
and insulin release, »982 
and shock 
insulin response to, »364 
HEPARIN 
and lipolysis, »342 
and lipoprotein lipase 
and oral contraceptives, »316 
release from alloxan diabetic rat 
heart, 149-155 
HEPATECTOMY 





and autoimmune disorders, »914 
and diabetes, »250 
and fasting triglycerides and choles-
terol in offspring of diabetic 
couples, »1044-1045 
and Huntington's chorea, »1121 
and diabetes onset 
and diet, »770 
and diabetic-like microangiopathy, »373 
and endocrine adenomatosis, »1122 
and hypercholesterolemia, »1121 
and lactose tolerance, 871 
and lipodystrophy and growth hormone 
abnormality, »771 
and obesity 
and insulin resistance and release, 
»316 
and renal glucosuria, »248 
and resistance to oral anticoagulants, 
»183 
HEXOKINASE 
and insulin release, 565 
in rat prostate glands 
and hormonal control, »185 
HEXOSE 
protein-bound 
and diabetes, 867 
transport 
in diabetic rats, »59 
uptake by brain, »315 
HEXOSE MONOPHOSPHATE SHUNT 
and dibutyryl cyclic AMP, 1033-1034 
HISTAMINE 
and insulin secretion, »248 
HISTONE PHOSPHORYLATION 
and cyclic AMP 
and insulin, 439-445 
HORMONES 
adenyl cyclase response to, »772 
and amino acids 
and infantile malnutrition, »182 
androgen 
and diabetic impotence, 23-28 
and calcium and insulin binding mech-
anisms, »1121-1122 
and cyclic AMP, »251 
and diabetic pregnancy, 31-35 
gastrointestinal 
and insulin response to triglycerides, 
928 
and hexokinase control in rat prostate 
glands, »185 
human chorionic somatomammotropin 
and insulin and glucagon release, 
1072-1075 
and insulin secretion, 539 
lipolytic 
fat cell response to, mercury and, 
»771 
lipolytic and glucocorticoid 
and diabetic ketosis, 946-954 
in pancreas, 536 
parathyroid 
and plasma insulin, »773 
and protein synthesis 
and cyclic AMP, »119 
sex 
and growth hormone secretion, »774-
775 
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sex steroids 
and liver triglyceride biosynthesis, 
»365 
HUNTINGTON'S CHOREA 
and diabetes, »374, »1121 
HYDROCORTISONE 
and liver mitochondrial structure, 258 
and rat fatty liver, »183 
HYDROCORTISONE SODIUM SUC-
CINATE 
and hypoglycemic coma, 961-962 
0-H YDROXYB UTYR ATE 
and lipolysis, »836 
and liver glucose production 




brain utilization of, »247 
D-3-HYDROXYB UTYR ATE 
uptake 
by isolated perfused rat brain, »1206 
3-HYDROXYBUTYRATE DEHYDROG-
ENASE 
in diabetic liver mitochondria, »184-185 
5-HYDROXYTRYPTAMINE 
and insulin secretion, »251-252 
HYPERALIMENTATION 
intravenous 
in children, »837 
HYPERAMMONEMIA 
and glucose metabolism 
and insulin, »184 
HYPERBILIRUBINEMIA 
neonatal 
and phenobarbitone therapy, »1123 
HYPERCALCEMIA 
and hyperparathyroidism, »773 
HYPERCHOLESTEROLEMIA 
and diabetes 




and diabetes, 108-112 
HYPERGLUCAGONEMIA 
alanine-induced 
and alpha-adrenergic blockade, »1043 
and insulin, 301-307 
HYPERGLYCEMIA 
and alcohol ingestion, »247-248 
and L-asparaginase therapy, »1119 
and chemical diabetes, »1121 
compared with ketosis, 257 
and diabetes 
in tuco-tuco, »1206 
and diet, »770 
in obese mice, »119 
and glucagon, »360-361 
and glucagon secretion 
and alanine, »183 
and growth hormone metabolic clear-
ance rates, 176 
and hemorrhagic shock, »364 
and hyperglucagonemia, 301-307 
and hypoglycemia 
and anti-insulin antibodies produc-
tion, 814-825 
and hypothalamic stimulation, »771 
insulin-resistant 
and aminophylline, »775 
and intravenous alimentation, »837 
and islet of Langerhans structure, »1043 
and liver cirrhosis, »356 
and metabolic acidosis and acute ure-
mia, 1109-1114 
and myocardial infarction 
and tolbutamide therapy, »122-123 
in Mystromys alhicaudatus, 716-721 
neonatal 
and insulin studies, »181 
and obesity 
and high-fat diet in mice, »182 
and pentobarbital, »836 
phenotiazine-induced, »184 
and phenytoin toxicity, »187 
and postheparin lipolytic activity, »342 
and splanchic nerve stimulation 
and andralectomy, »770 
and streptozotocin, »59 
and synthetic glucagon peptides, 845-
846 
and uterine relaxants, »1045 
and vascular disease, 679-680 
HYPERINSULINISM 
and adipose tissue resection, 13-15 
and chemical diabetes, »1121 
and diabetes 
and connective tissue changes, 733-
743 
and diabetic pregnancy, »912 
and insulin insensitivity, 6 
and insulin resistance 
in genetically obese rats, »838 
and liver cirrhosis, »356 
and liver glucose production, »380-381 
and obesity, »314, »380, 613, 617-618 
and blood proinsulin, 663-664 
and diet, »249 
and obesity and hyperlipidemia 
induced in monkeys, »1201 
HYPERLIPEMIA 
alcoholic, »770 
and diabetes, »123 
in gerbils, »70 
HYPERLIPIDEMIA 
and calcium, »980 
and cholesterol metabolism 
and Clofibrate, »1200-1201 
and metformin, »771 
and obesity and hyperinsulinemia 
induced in monkeys, »1201 
HYPERLIPOPROTEINEMIA, 744-752 
combined 
and diabetes and vascular disease, 
»376 
and cortisone acetate, »1044 
pediatric familial type I I 
and diet, »1043 
type I I , »1121 
and diet, »366 
HYPEROSMOLALITY 
and diabetes 
and ketogenesis, »369-370 
in galactose-fed chicks, »315 
HYPERPARATHYROIDISM 
and infant hypocalcemia, »914 
and plasma insulin, »773 
HYPERPHAGIA 
dietary prevention of, »337-338 
and polydipsia 




without diabetes, »769 
and glucose regulation, »776 
HYPERTHYROIDISM 
and thyroid function tests, 1012 
HYPERTRIGLYCERIDEMIA 
endogenous 
and plasma triglycerides synthesis, 
»55 
and insulin deficiency, »366-367 
and phenformin 
and insulin and free fatty acids, »380 
and plasma free fatty acid metabolism, 
»835 
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and postheparin lipolytic activity, *342 
and pregnancy, *365 
and streptozotocin diabetes 
and diet, *353-354 
HYPOCALCEMIA 
in infants of diabetic mothers, *914 
HYPOCHOLESTEREMIC DRUGS 
and tumor-bearing mice, *857 
HYPOGLYCEMIA 
and alcohol 
and basal insulin secretion, 65-69 
and arginine-induced insulin release, 
*312 
and biguanides 
and insulin, *123 
and cataracts 
in infants, *182 
and diabetes 
and kidney insufficiency, ° 1120-1121 
drug-induced, 955-962 
and exchange transfusions of citrated 
blood, °185 
factitious, °980 
and glixoxepid, *912 
and hyperglycemia 
and anti-insulin antibodies produc-
tion, 814-825 
and hyperparathyroidism, °773 
idiopathic 
and epinephrine excretion, *1200 
and infants, *248 
and beta cell nesidioblastosis, °189 
and glucose administration in diabetic 
mother, • 1202-1203 
and growth hormone levels, *250 
and insulin 
and central nervous system, *337 
and growth hormone, 22, 30 
and intravenous glucose, 610 
and iodinated insulin, *55 
ketotic 
diagnosis in children, *56 
and lactic acidosis, *1198 
liver response to 
and mannose, fructose and hydroxy-
butyrate, 797-803 
and metformin, *771 
and monamine oxidase inhibitor, *251-
252 
neonatal, * 179-180, *910 
nondiabetic reactive and asymptomatic 
biochemical 
and insulin-glucose dynamics, *373 
and oral insulin, 644, 645 
and pancreatoduodenectomy 
and pregnancy, *188 
and phenobarbitone, *1123 
reactive 
and phenformin therapy, °367-368 
and tolbutamide, *1123 
HYPOGLYCIN A 
and Jamaican vomiting sickness, *316 
HYPOGONADISM 
hypogonadotropic 
and diabetic impotency, 23, 26 
HYPOINSULINEMIA 
and alpha-adrenergic activity, *348 
HYPOKALEMIA 
and glucose intolerance, * 1043-1044 
HYPOLIPEMIA 
in pregnant rhesus monkeys, *912 
HYPOLIPIDEMIA 
in "acatalasemic" mice *56 
HYPOPHYSECTOMY 
and aminophylline 
and hyperglycemia, "775 
and diabetic pregnancy, 972-974 
and diabetic retinopathy, °349 
and glucagon secretion, °375 
and insulin secretion, *253 
and pancreatectomy 
and diabetic ketosis in rats, 946-954 




and growth hormone, *982-983 
and growth hormone levels, *776 
and hypoglycemia, *248 
HYPOTHALAMIC-HYPOPHYSEAL 
SYSTEM 
and insulin, *1200 
HYPOTHALAMUS 
damage 
and obesity, °1206 
lesions 
and insulin resistance and hyperinsu-
linemia, *838 
and lipolysis, °55 
stimulation 
and plasma glucose, insulin and glu-
cagon, *771 
ventromedial destruction 
in diabetic rats, *1043 
and glucose metabolism, * 1204-1205 
HYPOTHYROIDISM 
and diabetes, *769 
I 
IMMUNE COMPLEX DISEASE 
and diabetic microangiopathy, *352 
IMMUNOELECTROPHORESIS 
and diabetic glomerulosclerosis, 163-173 
and insulin antibodies assays, 816, 819 
IMPOTENCE 
and diabetes 
and androgenic function studies, 23-
28 
IMURAN 
and immune response to insulin, °58 
INDIA 




and glucose tolerance during preg-
nancy, *186 
congenital neuroblastoma and islet hy-
perplasia, 01122 
and Cushing's syndrome, *120 
of diabetic mothers 
and carbohydrate metabolism, *912, 
°1046 
and caudal dysplasia, *1042 
and drug-induced hypoglycemia, 955 
and hypocalcemia, °914 
and erythroblastosis fetalis 
and glucose metabolism, plasma in-
sulin and growth hormone se-
cretion, * 1199-2000 
and exchange transfusion 
of citrated blood, *185 
and glucose, *1120 
and hyperbilirubinemia 
and phenobarbitone therapy, °1123 
and hypoglycemia, *248 
and cataract, °182 
and glucose administration in dia-
betic mother, * 1202-1203 
hypoglycemic and normoglycemic 
and growth hormone levels, °250 
and ketoacidosis, * 181 
and malnutrition 
and metabolic and hormonal re-
sponses to amino acids, *182 
and marasmus 
and chromium and glucose utiliza-
tion, *313 
mortality 
and glucose tolerance during preg-
nancy, *186 
and neonatal hypoglycemia, 0179-180, 
«910 
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temporary, °181 
newborn 
and permanent diabetes, °249 
premature 
and intravenous hyperalimentation, 
°837 
and serum insulin and growth hor-
mone response to arginine and 
glucose, °316 
and severe idiopathic hypoglycemia 
and beta cell nesidioblastosis, *189 
and type I I hyperlipoproteinemia 




and plasma glucagon levels, *324 
rhinocerebral phycomycosis, °195 
INFRARED THERMOGRAPHY 
and circulation studies in diabetics, 
°981 
INSULIN 
action, 454-455, 485 
and amino acid sequences, 457-459 
and atomic structure, 509 
computer studies of, °347 
and insulin-dextran complex studies, 
*1122 
and insulin receptor, 396-401 
and lead intoxication, °381 
molecular basis of, 468-474, 695-700 
related to atomic structure, 492-505 
acute hypoglycemic action 
and insulin-dependent diabetes, *182 
acute response to glucose 
and epinephrine, °773 
and adipose tissuse lipolysis, 427 
administration 
to gastrointestinal tract in rabbit, 
203-207 
amino acid sequences, 485 
analogs synthesis, *772-773 
antibodies, »57, »182, °379, 649-656, 
657-659, 660, 677, »775, 764-
765, »769, 814-825, 914, 930-
934 
antisera 
proinsulin cross-reactivity with, 
465-466 
assays 
in monkeys, 1078-1089 
in obese rats, »1123 
and atherosclerosis, 684 
"big" 
and streptozotocin therapy for islet 
cell carcinoma, °1204 
"big" and "little", 677 
binding 
to lymphocytes and fibroblasts, 426-
427 
binding activity 
in diabetics and nondiabetics, *775 
and hormones, 01121-1122 
-binding proteins, 426 
bioassays 
and insulin stability determinations, 
805-812 
biosynthesis 
and amino acids, *772 
and cytochalasin B, 602-603 
monolayer newborn rat pancreas for 
study of, 627-630 
and blood glucose levels 
and exercise, 98-99 
and carbohydrate homeostasis, *357 
circulating antibodies to 
polyethylene glycol screening test for, 
»379 
concentrations 
and diabetic lipemia, °376-377 
content 
of beta cell tumors, 535 
of fetal rat pancreas, 193-201 
and cyclic AMP and dibutyryl cyclic 
AMP activity, 1028 




and glucagon secretion, °183 
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and glucose and fatty acid oxidation, 
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glucoreceptor mechanisms, 555-568 
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insulin secretion 
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and blood coagulation, 108-110 
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and insulin, 632-633 
steroid-induced, »54 
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and maternal caloric deprivation, 
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brain utilization of 
in normal and ketoacidotic rats, »247 
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and diabetes, 257-268 
and lipolysis suppression, »377 
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in fasted and diabetic rats, »246 
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and renal ammoniogenesis, »251 
and renal metabolism, »314 
and unstable diabetes, »836 
uptake by dog kidney, »251 
KETONURIA 
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and insulin deficiency, 414 
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and kidney function, »121 
lipoatrophic diabetes without, 827-830 
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hypokalemic nephropathy, »1042 
and insulin and proinsulin degradation, 
1091-1100 
DIABETES: V O L U M E 21 (1972) PAGE NUMBERS BY ISSUE 
January, 1-64 Supplement 1, 321-384 August, 843-922 
February, 65-128 Supplement 2, 385-714 September, 923-986 
March, 129-192 June, 715-778 October, 987-1050 
April, 193-256 July, 779-842 November, 1051-1130 
May, 257-320 December, 1131-1210 
26 




polyalanyl insulin, °835 
of progeny of protein-deficient rats, 
•1041 
and starvation 
and mineralcorticoid and glucagon 
sensitivity, *334 
transplantation 
and diabetes, °322 
and pancreas transplantation, °355 
uric acid excretion 
and nicotinic acid, *313 
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incorporation into growth hormone and 
lipids, *187 
LEUKEMIA 
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and streptozotocin, °59 
and tissue injury, *315 
mitochrondria 
and diabetic ketosis, 257-268 
mitochrondrial swelling 
and ammonia toxicity, 0835-836 
a-oxoglutarate carboxylation and dia-
betes, *981 
perfused rat 
and amino acid metabolism, °57 
and glucocorticoids and gluconeo-
genesis, *252 
potassium flux and glucose output 
studies, °254 
perfused sheep, * 57-58 
and plasma angiotensinogen and renin 
levels, *253 
plasma membrane 
and calcium and insulin binding 
mechanisms, °1122 
and insulin receptors of, °335 
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and pancreas metabolism, 562-564 
D-MANNOHEPTULOSE 
and insulin response to glucose, 541 
MANNOSE 
and insulin secretion, 539, 543 
and liver glucose production 
and insulin-induced hypoglycemia, 
797-803 
D-MANNOSE 
and alloxan toxicity, »123 
MARASMUS 
and glucose utilization 
and chromium, »313 
MARIHUANA 
and hypoglycemia, 961 
MARKS, HENRY E., 178 
MARMOSETS 
and diet-induced jejunal lipodystrophy 
»248 
MAURIAC SYNDROME, 633 
MEBANAZINE 
and insulin 
and hypoglycemia, 960 
MENSTRUATION 
and carbohydrate and lipid metabolism, 
»1204 
and growth hormone secretion, »774-
775 
MENTAL ILLNESS 
and sulfonylureas, 959 
MENTAL RETARDATION 
and galactosemia, 202, 208 
6-MERCAPTOPURINE 
and immune response to insulin, »58 
MERCURY 
and fat cell response to insulin and 
lipolytic hormones, »771 
METABOLISM 
adipose tissue 
and glycerol kinase regulation by in-
sulin, »122 
and insulin, 414-424 
and obesity, 6-11, »54 
and adipose tissue fat cell size and 
number, »180 
in African pygmies, * 1045-1046 
amino acids 
and exercise, »770-771 
and glucagon and insulin, °340-341 
and glucose, »56 
and infantile malnutrition, »182 
in perfused rat liver, »57 
and starvation during pregnancy, 
»1118-1119 
and arginine derivatives, 01122-1123 
and blood proinsulin and C-peptides, 
669 
brain, »315 
and galactose toxicity, 202, 208 
and hepatic response to insulin-in-
duced hypoglycemia, 802-803 
and ketoacidosis, »247 
brain glucose 
in newborn rat, »775 
calcium, °326-327 
carbohydrate 
and adrenergic agents, »1203 
and age, »183-184 
and alcohol, »247-248 
and catecholamines and methylpred-
nisolone, »772 
and diabetic microangiopathy, 872 
in infants of diabetic mothers, »1046 
and metformin, »914 
in newborn infants of diabetic 
mothers, »912 
and pancreatic enzymes, »186 
and psoriasis, »250 
carbohydrate and lipid 
and glucose tolerance and insulin re-
sponse to glucose, »1119 
and menstrual cycle, »1204 
and streptozotocin, »59 
cholesterol 
and Clofibrate, »1200-1201 
and insulin, »186 
ethanol and sorbitol 
in hypo-, hyper-, and euthyroid rats, 
»181 
fat cell 
and dibutyryl cyclic 3', 5' AMP, »343 
and insulin, »351-352 
fat and lactate 
and phenformin, »1045 
fatty acids 
by sheep liver and viscera, »118 
and thrombin, »312 
fetal 
and starvation, »187 
forearm 
and tolbutamide, »1206 
free fatty acids, »835 
fructose 
and insulin, »314 
gastrin 
and secretin, »249 




of adipose tissue, 1151-1161 
and carcinoid syndrome, »1200 
and dosage, 1102-1108 
and erythroblastosis fetalis, »1199-
1200 
and exercise and dietary carbohy-
drate, »179 
in hyperammonemic rats, »184 
and insulin and proinsulin, 935-938 
in isolated pancreas islets, 538-545 
in isoproterenol-stimulated rat saliv-
ary glands, »982 
and leg exercise, »776 
and methylene blue, »350 
in rat skin, »189 
and shock, »1201 
and ventromedial hypothalamus nu-
clei destruction, »1204-1205 
glucose and fatty acids 
and pancreas alpha and beta cells, 
»909 
glucose C-14 
and 6-aminonicotinamide, »1198 
U-C-14-glucose, xylitol, fructose, and 
sorbitol 
in fasted and streptozotocin diabetic 
rats, »122 
glycosaminoglycans 
and alloxan diabetes, 1162-1166 
growth hormone 
and juvenile diabetes, 175-177 
and short stature, »119-120 
and insulin clearance, 1003-1011 
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of isolated pancreas islets in tissue cul-
ture, 546-553 
isolated perfused sheep liver, »58 
ketone bodies 
in fasted and diabetic rats, »246 
in perfused skeletal muscle, °343 
kidney, »910 
lactate 
and ethanol, »367 
lipid 
in dogs, »312 
and lipoatrophy, »381-382 
liver, 50-52 
and anti-insulin serum, 280-288 
and diabetic ketosis, 257-268 
and glucagon, »55 
and glucagon:insulin ratio, »341 
and insulin, 453, »1200 
and insulin and cyclic AMP levels, 
439-445 
and rapid indicator-dilution technic 
studies, »180 
and tissue injury, »315 
mammary cell 
and insulin, °315 
and obesity 
and exogenous growth hormone, 
»1046 
ornithine, »771 
pancreatic beta cell 
and phlorizin, »910-911 
pancreatic islet 
and glucose, »344-345 
placental glycogen 
and diabetes, 1185-1190 
and prediabetes, 685-693 
proinsulin, »347 
protein 
and insulin, 447-451 
renal, »314 
triglyceride and insulin, 923-928 
METABOLITES 
and glucose 
in perfused pancreas, 564-565 
islet cell, 571 
and insulin secretion, »344-345 
METAFORMIN 
and carbohydrate metabolism 
in obese, nondiabetic women, »914 
and hyperlipidemia, »771 
and hypoglycemia, »771 
METHAMPHETAMINE 
-induced insulin release, »252 
METHIONINE 
and pancreas mitotic activity, 1055 
and pancreatic beta cell uptake of amino 
acids, »772 
and rat fatty liver metabolism, »183 
L-METHIONINE 
and pancreas a-amino-isobutyric acid 
transport, »181 
METHOTREXATE 
and immune response to insulin, »58 
3-O-METHYL-D-GLUCOSE 
excretion 
and metformin, »771 
intestinal uptake, »249 
transport 
and biguanides, »119 
N-METHYLBENZYLAMINE, 
and insulin secretion, »248 
METHYLCHOLANTHRENE 
-induced thyroiditis 
and autoimmunity, »253 
METHYLENE BLUE 
and glucose metabolism and insulin se-
cretion, »350 
METHYLPHENIDATE 
and tumor-bearing mice, »837 
METHYLPREDNISOLONE 
and carbohydrate metabolism, »772 
METHYSERGIDE MALEATE 
and insulin secretion, »315-316, 779-
787 
MICROANGIOPATHY 
and bacteriuria, »118 
and diabetes, 680-681 
and age, »837 
diabetic 
and concurrent bullous and atrophic 
skin lesions, »251 
in humans and animals, »357 
and insulin and gamma globulin in-
teractions, 872-879 
and muscle capillary basement mem-
brane changes, 881-896, 899-
905 
and polyol metabolism, galactosemia, 
and immune complex disease, 
»352 
and serum protein changes, »371 
diabetic-like, »373 
and glucose tolerance, »321 
MICROSCOPY 
electron 
and abetalipoproteinemia, »60 
of beta cell tumors, 535 
capillary basement membrane, »118 
of depancreatized baboon kidney, 
»338 
of diabetic rat liver, 259-260, 264-
268 
of endocrine pancreas in newborn 
rodents, 1051-1059 
of glomerular basement membrane 
of juvenile diabetics, »913 
and intestinal lipoprotein production, 
»121 
and islets of Langerhans, »1043 
of mouse pancreatic beta cells, 1068-
1070 
and muscle capillary basement mem-
brane changes, 882, 884-896 
of pancreas of diabetic monkeys, 
1086, 1087 
and pancreatic islets, 595-603 
of testicular tissue, 25-28 
light 
of isolated islets in tissue culture, 
547-553 
light and electron 
of human embryonic and fetal pan-
creatic islets, 511-533 
and islet cell changes in streptozo-
tocin diabetic rabbits, 129-
137 
pancreas 
and long-term juvenile diabetes, 115-
116 
of pancreatic islets 
from cyproheptadine-treated rats, 71-
78 
in late-onset diabetes, 763-767 
MINERALOCORTICOID 
kidney sensitivity to 
and starvation, »334 
MINERALS 
calcium, magnesium and phosphorus 
flux 
and glucose ingestion in children, 
»376 
and insulin secretion, 570 
lead intoxication 
and insulin action, »381 
zinc 
and insulin, 497-498, 509 
MONKEYS 
and glucose tolerance tests 
and bedrest and exercise, 105 
and induced obesity, hyperinsulinemia 
and hyperlipidemia, »1201 
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Macaca nemestrina 
and streptozotocin diabetes induced 
by direct pancreatic infusion, 
138-141 
Macaca nigra 
spontaneous diabetes in, 1077-1089 
rhesus 
and insulin response to hemorrhagic 
shock, *364 
and jet insulin injections, 39-44 
MONOAMINE OXIDASE 
in mouse pancreas, *120 
MONOAMINE OXIDASE INHIBITORS 
and hypoglycemia, °251-252 
and insulin release, *363-364 
MONOAMINES 
and insulin secretion, 779-787 
MONOGLYCERIDASE 
postheparin, 0 54 
MONOGLYCERIDE HYDROLASE 
in obese hyperglycemic mice, *186 
MORTALITY 
and Cushing's syndrome in infancy, 
*120 
and diabetes, *1044 
and arteriosclerosis, *1123 
and insulin, 633-636 
fetal 
and maternal blood sugar levels, 
*1201-1202 
and galactose toxicity in chicks, 208 
and heart disease 
and Clofibrate therapy, *838 
and lactic acidosis, °1198 
and renal transplantation 
and diabetes, *322 
and sulfonylurea treatment, *120 
and tolbutamide 
in UGDP study, 1036-1037 
and x-irradiation in mice, *914 
MOUSE 
acomys cahirinus 
and defective immunoreactive insulin 
secretion, 1060-1070 
and alloxan 
and diphenylhydantoin, 80-83 
and anti-insulin serum 
and pancreatic islet studies, *911 
diabetic 
and glomerular lesions and protein-
uria, *1120 
and diabetic-like microangiopathy, *373 
and encephalomyocarditis virus infec-
tion 
and diabetes-like syndrome, °247 
hyperglycemic 
and pancreas a-amino isobutyric acid 
transport, *181 
and insulin release 
and methamphetamine, *252 
islets 
and insulin release, *328-329, *914 
longevity and mortality distribution 
studies, °914 
and microangiopathy, *357 
mutant "acatalasemic" 
and hypolipidemia, *56 
obese, *1044 
and adipose tissue glycerol kinase 
and lipolysis, *911-912 
and glycerol kinase regulation, *122 
and insulin resistance, * 314-315 
and plasma growth hormone, °122 
with transplanted tumors, *774 
obese hyperglycemic 
and adipose tissue monglyceride hy-
drolase, *186 
and caloric restriction studies, *835 
and diet, °119 
and exogenous insulin, *344 
and high-fat diet, *182 
and insulin release and citrate studies, 
999-1001 
obese and lean 
and islets of Langerhans adenyl cy-
clase and phosphodiesterase, 
*179 
pancreas 
and encephalomyocarditus virus in-
fection, *338-339 
tumor-bearing 
and hypocholesteremic drugs, *837 
MUCOPOLYSACCHARIDES 
metabolism 
and psoriasis, ft250 
MUMPS 
and diabetes, *182, 766 
MUSCLE 
alanine synthesis 
and exercise, * 770-771 
amino acids 
and exercise, *119 
ammonia production, *1203 
antibody to 
binding to fibroblasts, *314 
capillaries basement membrane changes, 
*254 
and aging and diabetes, 881-896, 
899-905 
capillary permeability and blood flow 
and diabetes and prediabetes, *769 
and ethanol, *838 
and insulin and proinsulin degradation, 
1091-1100 
myopathy 
and capillary basement membrane 
thickening, *118 
phosphofructokinase 
and cyclic AMP and dibutyryl cyclic 
AMP, °363 
and sepharose-bound insulin, *335-336 
skeletal 
ketone-body metabolism in, *343 
lactate metabolism and ethanol, *367 
protein turnover in, *341 
MYOCARDIAL INFARCTION, 763 
and Clofibrate therapy, *838, *910 
and glucose tolerance, *184 
and glucose tolerance tests, *312-313 
and hormone and metabolic disturb-
ances, *119 
and hyperglycemia 
and tolbutamide therapy, * 122-123 
MYOTONIC DYSTROPHY 
and insulin secretion, *378 
MYSTROMYS ALB1CAUDATUS 
pancreatic islet structure studies, *1043 




and oral insulin, 645 
NEPHRECTOMY 
and uremia 
and insulin release, °910-911 
NERVOUS SYSTEM 
and adenyl cyclase, *773 
autonomic 
and insulin release, 624-627 
central 
insulin-sensitive receptor in, *337 
conduction 
in galactose-fed rats, 295-300 
and diabetic impotence, 23 
disease 
and hypoglycemia, *248 
and growth hormone release, *913 
and impotence 
and diabetes, 23-28 
and lipolysis 
and 0-hydroxybutyrate, *836 
and phenothiazine-induced hypergly-
cemia, *184 
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sensory perception thresholds 
and diabetes, »1199 
splanchic nerve stimulation, »770 
tissue 
and insulin binding proteins, 427 
sorbitol and fructose, blood sugar 
control and, 1173-1178 
NEUROBLASTOMA 
congenital 
and islet hyperplasia, »1122 
NEUROPATHY, DIABETIC 
and diabetes management, 679 
galactosemic, 295-300 
of hands, »314 
and impotence, 23-28 
and prediabetes, »359 
N I A L A M I D E 
and insulin release, »363-364 
NICOTINAMIDE 




and insulin, »315 
NICOTINIC ACID 
and glucose tolerance, plasma insulin, 
and uric acid excretion, »313 
NIGERIA 





and steroid-induced ketoacidosis, »54 
NORADRENALINE 
and blood glucose and free fatty acid 
responses to catecholamines, 
»912 
NOREPINEPHRINE 
and fat cell metabolism, 420 
and glucose tolerance tests, »348 
and insulin release 
and prostaglandins, »329 
pressor response to 
and insulin treatment in alloxan dia-
betic rats, »354-355 
and theophylline 
and cyclic AMP, 417 
NUCLEOTIDES 
and glucagon, 440 
NUTRITION, »59. See also Diet; Malnu-
trition; Starvation 
and insulin secretion, 606-615, 617-618 
postnatal 
and kidney cellular development in 




and adipose tissue 
fat cell size and metabolism, »54 
glycerol kinase and lipolysis, »911-
912 
monoglyceride hydrolase, »186 
and caloric restriction, »835 
and cardiovascular disease, »980 
in children 
and glucose tolerance tests, »1042-
1043 
and diabetes, »246, »250 
and low calorie diet with phenter-
mine resin, »361 
and phenformin, »362 
and diabetes prevalence, »776 
and ethanol 
and phenformin, »363 
and exercise 
and insulin secretion, »909 
and food intake 
and plasma glucagon, »331-332 
•and glucose tolerance, 1012, »1205 
and growth hormone administration, 
»1046 
and hyperglycemia 
and high-fat diet in mice, »182 
and hyperinsulinemia, »380, 613, 617-
618 
and adipose tissue resection, 13-15 
and beta cell hyperplasia and in-
sulin resistance, »314 
and blood proinsulin, 663-664 
and diet, »249 
and hyperinsulinemia and hyperlipi-
demia 
induced in monkeys, »1201 
and hypothalamic damage, »1206 
and insulin assays, »1123 
and insulin resistance, »314-315, »370 
and insulin resistance and release, »316 
and insulin secretion 
and alcohol hypoglycemia, 65-69 
and body composition, »1118 
and xylitol and glucose, »187-188 
and insulin sensitivity of adipose tissue, 
6-11 
and metformin 
and carbohydrate metabolism, »914 
in new strain of mouse, »1044 
and plasma growth hormone response 
to hypoglycemia and arginine, 
»312 
and proinsulin response to oral glucose, 
»356 
and weight reduction 
and adipose tissue lipolysis and cellu-
larity, 754-760 
OBITUARIES 
Beardwood, Joseph T., Jr., 839 
Marks, Henry E., 178 
OCTANOATE 
and fat cell lipolysis, 418, 419, 421 
and growth hormone synthesis, »187 
OLEATE 
and fat cell lipolysis, 418, 419 
OLIGOMYCIN 
and insulin release 
in fetal rat pancreas, »121 
ORAL CONTRACEPTIVES 
and plasma lipids, lipoproteins, and in-
travenous fat tolerance, and 
post-heparin lipoprotein lip-
ase activity, »316 
ORAL HYPOGLYCEMIC AGENTS 
and diabetic mortality, »1044 
di-isopropylammonium dichloracetate, 
»358 
labeling laws, 833,1116-1117 
and vascular disease, »57 
ORNITHINE 
utilization 
by chick, »771 
ORPHENADRINE 
-induced hypoglycemia, 961 
ORTHOPHOSPHATE 
and liver threonine dehydratase, »980-
981 
OUABAIN 
and glucose-induced biphasic insulin 
release, »246 
and insulin secretion, »913 
OXYGEN 
consumption by spanchnic bed, 50-51 
myocardial consumption of 
and glucagon, »118-119 
uptake 
in diabetic rat liver, 257-268 
of isolated islets in tissue culture, 
547-548, 550 
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OXYTETRACYCLINE 
and insulin 
and hypoglycemia, 960 
P 
PALMITATE 
and glucose metabolism, 419 
and growth hormone synthesis, *187 
metabolism 
and ketosis, 258, 259, 261, 267 
PANCREAS 
acinar atrophy and fibrosis 
and hemolytic anemia, *773-774 
of acomys cahirinus, 1068-1070 
and alloxan 
and diphenylhydantoin, 81-83 
alpha and beta cells 
and glucose and fatty acid oxidation, 
°909 
alpha cell function 
and diabetes, 301-307 
amino acid metabolism 
and glucose, *56 
anglerfish islets 
and glucagon biosynthesis, *58-59 
beta cell dysfunction 
and diabetes, 703-704 
beta cell metabolism 
and phlorizin, °910-911 
beta cell nesidioblastosis 
in idiopathic hypoglycemia of in-
fancy, *189 
beta cell C-peptide 
immunoreactivity studies, 1013-1025 
beta cell responses, 619-630 
beta cell structure, 536 
beta cell tumors, 535 
beta cell webs 
and insulin secretion, *838 
beta cells 
alanine, arginine and leucine uptake 
by, *772 
and alloxan and streptozotocin, *326 
and amines, °248 
and a-amino-isobutyric acid trans-
port, *181 
and arginine, *312 
calcium uptake assays, *837 
and cyclic AMP, *329 
of cyproheptadine-treated rats, 71-78 
embryonic, 523, 528, 531-533 
and encephalomyocarditis infection, 
*247 
and glucose-induced insulin release, 
594-603, 605 
and glucose protection from alloxan 
toxicity, *123 
insulin detection study, °246 
and insulin secretion, °914 
intracellular pH, *911 
and obesity, *314 
replication, °346 
and sensitivity to glucose in predia-
betes and diabetes, 224-233 
and sulfonylurea-induced insulin re-
sponse, *122 
vital damage, 713-714 
blood flow and insulin output 
and exogenous insulin, *1204 
citrate levels 
and insulin release and inhibition, 
999-1001 
cultured fetal human, °345-346 
of diabetic monkeys, 1086,1087 
duct-ligated 
response to glucose, 0344-345 
early research, 385-395 
endocrine 
structure in newborn rodents, 1051-
1059 
endocrine cells 
in embryos, 519-523 
enzyme activity 
in rats, *59 
enzymes 
and dietary regulation, *186 
exocrine 
and diet, *186 
fetal, 620, 621, 623-624 
fetal and embryonic, 536 
fetal endocrine 
cytological studies, *253-254 
fetal rat 
insulin content study, 193-201 
insulin release and inhibition stud-
ies, °121 
glucagon 
and sulfonylureas, 216 
glucagon and insulin secretion 
and beta adrenergic and cholinergic 
agents, *332 
golden hamster cell cultures 
and insulin secretion study, *370 
insulin 
and glucose, *375-376 
insulin output and blood flow 
and prostaglandins, *369 
insulin release 
and calcium, 591-592 
and hemorrhagic shock, *982 
and insulin secretion, 510 
and diphenylhydantoin and diazox-
ide, 856-861 
and species variation, °184 
and sulfonylureas, *1120 
islet cell adenoma 
and adenyl cyclase activation by glu-
cagon and tolbutamide, °912 
cyclic AMP content, glucose, glu-
cagon, tolbutamide and theo-
phylline and, *346-347 
and factitious hypoglycemia, *980 
islet cell carcinoma 
circulating insulin in, *909-910 
and streptozotocin, *1204 
islet cell tumors 
and immunoreactive glucagon, *333 
and plasma proinsulin, *1204 
proinsulin content, 675-676 
and proinsulin-like component of in-
sulin, *313 
islet hyperplasia, 536 
congenital, °1122 
islet insulin secretion 
and exogenous insulin, °344 
islets 
and 6-aminonicotinamide, °1198 
and anti-insulin serum, *911 
calcium efflux from, *326-327 
cyclic AMP levels, starvation and, 
*329 
in diabetic guinea pigs, *338 
and electrical activity in response to 
leucine and tolbutamide, *345 
embryogenesis, 511 -533 
hypertrophy and beta cell hyper-
plasia in long-term juvenile 
diabetics, 114-116 
and insulin release, 571 
and insulin release and content, 
*1205 
and insulin resistance factor secretion, 
*370 
insulin secretion and glucose metab-
olism, 538-545 
and late-onset diabetes, 762-767 
metabolism, 546-553 
monoamines, °120 
pyridine nucleotide depletion, 789-
792 
response to glucose, *344-345 
and streptozotocin diabetes, 129-137 
structure, 536-537, *1043 
ultrastructure studies, °120 
isolated perfused rat 
and human chorionic somatomam-
motropin effects on insulin 
and glucagon release, 1072-
1075 
isolated rat islets 
perifusion, 987-997 
monoamines 
and insulin secretion, *345, 779-787 






Supplement 1, 321-384 









SUBJECT INDEX 1972 
monolayer cultures 
and insulin biosynthesis studies, 627-
630 
mouse 
and monoamines, »251-252 
perfused canine 
and glucagon secretion studies, »314 
perfused rat 
and insulin release studies, »55, »56, 
»369 
rat 
endocrine function in monolayer cul-
tures of, »368 
and ouabain and insulin release, »246 
rat islets 
and alloxan and glucose interactions, 
»326 
and methylene blue, »350 
scintiphotoscanning, »351 
and streptozotocin-induced beta cell 
toxicity 
and nicotinamide and pyridine nu-
cleotides, »325-326 
streptozotocin infusion 
in Macaca nemestrina, 138-141 
transplantation 
in diabetic subject, »355 
tumors 
insulin secreting, »1120 
PANCREATECTOMY 
and discovery of insulin, 385-394 
and glucagon 
and cyclic AMP, 453 
and glucose turnover 
and insulin and glucagon infusion, 
»382-383 
and hypophysectomy 
and diabetic ketosis in rats, 946-954 
and liver free fatty acid metabolism, 280 
and liver 3-hydroxybutyrate dehydro-
genase, »184 
subtotal 
and Chlormadinone acetate, »313 
PANCREATITIS 
acute 
diabetes incidence after, »911 
and oral insulin, 646-647 
PANCREOZYMIN 
and insulin release, 928 
PARAPLEGIA 
and impotence 
and androgenic function, 23-28 
PARATHORMONE 
action 
and cyclic AMP, »251 
PARATHYROIDECTOMY 
and plasma insulin levels, »773 
PARKINSON'S DISEASE 
and L-dopa 
and plasma growth hormone, insulin, 
and thyroxine, »911 
PENTOSE PHOSPHATE PATHWAY 
and insulin, »315 
and insulin release, 143 
overactivity 
and psoriasis, »250 
and xylitol absorption, »352 
PEPSIN 
secretion 
and secretin and duodenal acidifi-
cation, »250 
C-PEPTIDE 
in blood, 661-670 
circulating immunoreactivity studies 
and diabetes, 1013-1025 




and glucagon, 843-855 
C-terminal, 714 
PEROXIDASE 
and hypolipidemia, »56 
pH 
arterial 
and acidosis diagnosis, 1110 
of inflammatory exudates 
in acidotic diabetic rabbits, »1201 
intracellular 
of pancreatic beta cells, »911 
PHENFORMIN 
and ethanol 
and obesity and prediabetes, »363 
and fat and lactate metabolism and in-
sulin production 
and starvation, »1045 
and glibenclamide, »55 
and lactic acid levels 
and anoxia and exercise, »351 
and lactic acidosis, »1198 
lipicl-lowering effect of, »380 
and lipomatosis, 15 
and obese diabetics, »362 
and reactive hypoglycemia, »367-368 
UGDP study of, 976-978 
and vascular disease, »57 
PHENOBARBITONE 
and blood sugar, »1123 
PHENOTHIAZINE 
-induced hyperglycemia, »184 
PHENOXYBENZAMINE 
and diazoxide-induced insulin secretion, 
»1045 
and insulin secretion, 783-784 
PHENTERMINE RESIN 
and low-calorie diet 
and obese diabetics, »361 
PHENTOLAMINE 
induced alpha-adrenergic blockade 
and insulin release, »181 
and insulin secretion, »248 
and exercise, »119 
L-PHENYLALANINE 
and cholecystokinin release, »252 
-induced insulin release, »369 
ß-PHENYLETHYLAMINE 
and insulin secretion, »248 
PHENYLETHYLBIGUANIDE 
and liver gluconeogenesis, »910 
PHENYLISOTHIOCYANATE 
degradation studies, »835 
PHENYTOIN 
and hyperglycemia, »187 
PHEOCHROMOCYTOMA 
and insulin-dependent diabetes, »838 
PHLORIZIN 
and brain uptake of D-glucose, »315 
and intestinal fructose uptake, »249 
and pancreatic beta cell metabolism, 
»910-911 
PHOSPHATE 




and cyclic AMP and cyclic GMP, »838 
and insulin release, »328-329 
in islets of Langerhans 
of obese and lean mice, »179 
PHOSPHENOLPYRUVATE CARBOXY-
KINASE 
and cyclic AMP 
and insulin, 439-445 
PHOSPHOFRUCTOKINASE 
and cyclic AMP and dibutyryl cyclic 
AMP, »363 
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6-PHOSPHOGLUCONATE DEHYDRO-
GENASE 
in jejunal mucosa 
and alloxan diabetes, *188 
PHOSPHOLIPIDS 
levels 
and alloxan diabetes, 1163-1166 
PHOSPHORUS 
flux 
and glucose ingestion in children, 
*376 
PHOSPHORYLASE 
and synthase, 430 
PHOSPHORYLATION 
fatty acid 
and diabetes, 257-268 
PHOTOCOAGULATION 
argon laser 
and diabetic retinopathy, *189 
PHYTOHEMAGGLUTININ 
peripheral blood lymphocyte response 
to 
and diabetes, 906-907 
PIMA INDIANS 
and diabetes, *180 
and kidney disease, *365-366 
and viral hypothesis, 766 
PITUITARY GLAND 
ablation 
during diabetic pregnancy, 972-974 
diabetogenic polypeptide from, *837 
and glucagon secretion, *375 
growth hormone synthesis 
and lipids, *187 
protein synthesis 
and insulin, *1200 
reserve capacity 
and diabetes, *981 
PLACENTA 
glycogen metabolism 
and diabetes, 1185-1190 
glycogenesis 
and insulin, *1199 
insulin degradation by, * 374-375 
lactogen 
and diabetic pregnancy, 32-33 
and insulin and glucagon release, 
1072-1075 
and maternal diabetes, *315 
and nitrogen conservation during preg-
nancy, *340 
polyol pathway, *329-330 
enzymes of, *330 
and streptozotocin, °316 
PLASMA 
amino acids 
and exercise, *119 
glucagon and insulin control of, °340-
341 
and starvation, 0179 
angiotensinogen and renin 
regulation by liver, *253 
L-asparagine 
and hepatic homeostasis, °254 
catecholamine 
during oral glucose tolerance test, 
*348 
cholesterol 
and diet, *1043 
cholesterol and triglycerides 
and Clofibrate, * 1200-1201 
fasting growth hormone levels 
and diabetic retinopathy, *322 
free fatty acids 
conversion to plasma triglyceride 
fatty acid, *835 
and glucagon infusion in congestive 
heart failure patients, 942, 
944 
and menstrual cycle, *1204 
uptake by liver, 947-948, 950-954 
free fatty acids and glucose 
and L-dopa, *1121 
free fatty acids, glucose, insulin, and 
ketones 
and sodium linoleate infusion, 1179-
1184 
free fatty acids and insulin 
in malnourished infants, *182 
free fatty acids and ketone 
and insulin secretion, 923 
free fatty acids metabolism 
and anti-insulin serum, 280-288 
glucagon 
and diabetes, *324 
and exercise, * 1198-1199 
and food intake, °331-332 
and infection, *324 
and sulfonylureas, 216-223 
glucagon, growth hormone and insulin 
and glucose during exchange trans-
fusions, *1120 
glucose 
and graded insulin infusions, *379 
and growth hormone secretion, *774-
775 
glucose and free fatty acids 
and pentobarbital, *836 
glucose, free fatty acids, Cortisol and 
growth hormone 
and growth hormone administration, 
22, 30 
glucose and immunoreactive insulin 
and adipose tissue resection, 13-15 
glucose, insulin and glucagon 
and hypothalamic stimulation, *771 
growth hormone 
clearance, 175-177 
and juvenile diabetes, *312 
in obese mice, °122 
during sleep, °776 
growth hormone, insulin and thyroxine 
and L-dopa, °911 
growth hormone responses 
and Cushing's syndrome, *1122 
growth hormone and sulfation factor 
in African pygmies, * 1045-1046 
hyperosmolality 
and hyperglycemia, °837 
immunoreactive insulin 
in acomys cahirinus, 1060-1070 
during continuous blood glucose 
monitoring in diabetics, *324-
325 
and insulin administration to gas-
trointestinal tract, 203-207 
and surgery for islet cell adenomas, 
*185 
and weight reduction, * 1118 
insulin 
and adipose tissue fat cell size and 
number, °180 
and atherosclerosis, *253 
and diet, *249 
and erythroblastosis fetalis, *1199-
1200 
and glucose, *375-376 
and hyperparathyroidism, *773 
and hypokalemia, * 1043-1044 
in kwashiorkor, * 1119-1120 
and metabolic insulin clearance, 
1003-1011 
and metformin, *771 
and methamphetamine, °252 
and nicotinic acid, *313 
and obesity and exercise, °909 
and pancreatic alpha cell response 
to hyperglycemia, 301-307 
response to glucose, 226-233 
and theophylline, °180 
insulin and blood glucose 
and obesity, *54 
insulin, glucose and free fatty acids 
and insulin-treated diabetes, *325 
insulin and glucose response to glucose 
loading 
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and diet and fasting, »1046 
insulin and triglycerides 
seasonal variations in, »312-313 
insulin and uric acid 
and nicotinic acid, °313 
isovaleric acid and a-methylbutyric acid 
and hypoglycin A, »316 
lipase activity 
and heparin, 152-153 
lipids 
and diet, »366 
and glucagon, »311-312 
and glucose tolerance tests, °383 
and pregnancy in rhesus monkeys, 
°774 
lipids and lipoproteins 
and oral contraceptives, »316 
membrane vesicles 
and glucose transport, °1042 
membranes of fat cells 
and insulin, 403-411 
osmolality 
and serum osmolality, lactic acid 
values and, »838 
and platelet aggregation, »355 
proinsulin 
assay, »122 
and islet cell tumors, »1204 
proinsulin-like components of, 673-676 
testosterone 
and diabetic impotence, 23-24 
triglyceride removal 
and hyperglycemia, °342 
triglycerides 
and adipose tissue fat cell size and 
number, »180 
and exercise, »909 
and fasting, »54 
and glucagon, »55 
synthesis, »55 
triglycerides and cholesterol 
and cortisone acetate, »1044-1045 
tryptophan 
and insulin, »909 




and adrenalectomy and hypophysec-
tomy, »358-359 
POLYETHYLENE GLYCOL 




and diabetic microangiopathy, »352 
POLYOL PATHWAY 
activity 





from pituitaries, »837 
synthesis, 476-484 
POSTHEPARIN LIPOLYTIC ACTIVITY 
deficiency in 
and hyperglycemia, »342 
POTASSIUM 
and antinatriuretic effects of carbohy-
drate, »772 
flux 
and insulin and adenosine 3', 5'-
monophosphate, »254 
and insulin action, 697-698 
and insulin secretion, 570 
myocardial 
and glucagon, »118-119 
and prostaglandins 
and growth hormone secretion, »313 
uptake and loss 
and cyclic AMP and insulin, 439-445 
POTASSIUM PARA-AMINOBENZOATE 
and hypoglycemia, 960 
PREDIABETES 
and beta cell sensitivity to glucose, 224-
233 
and caffeine 
and glucose tolerance tests, »365 
in children, 45-47 
in Chinese hamster 
and prevention of diabetes, »337-338 
and diabetes prevention, »337-338, 693 
and diabetic neuropathy, »359 
and ethanol 
and phenformin, »363 
and glucose tolerance, »321 
and hypoglycemia 
and insulin-glucose dynamics, »373 
and insulin secretion, »314, 688-691 
and liver sensitivity to endogenous in-
sulin, »323-324 
and low insulin response, 685-687 
and plasma lipids during glucose tol-
erance tests, »383 
and retinal blood flow, »354 
and transition to diabetes, 691-693 
PREDNISOLONE 
and immune response to insulin, »58 
PREGNANCY 
and amino acid metabolism 
and starvation, »1118-1119 
and biliary lipids, »912 
and caloric deprivation 
and maternal and amniotic fluid sub-
strate level, »1202 
and glucose tolerance test indications, 
»186 
and human chorionic somatomammo-
tropin 
and insulin and glucagon release, 
1074-1075 
and hypoglycemia following pancreato-
duodenectomy, »188 
and insulin response 
and arginine, »251 
and liver triglyceride biosynthesis, »365 
and maternal protein restriction 
and postnatal growth hormone pro-
duction and bone develop-
ment, »1047 
and placental nitrogen conservation, 
»340 
in rhesus monkeys 
and plasma lipid levels, »774 
and uterine relaxants 
and hyperglycemia, »1045 
PREGNANCY, DIABETIC 
and blood sugar levels 
and perinatal mortality and morbid-
ity, »1201-1202 
and fetal and placental composition, 
»315 
and glucose tolerance tests in neonates, 
»912 
and hypophysectomy for diabetic ret-
inopathy, 972-974 
and insulin deficiency 
and endogenous hypertriglyceride-
mia, »366-367 
and laboratory studies, 31-35 
and lactosuria, 1195 
and phyocomelic diabetic embryopathy 
syndrome, »1042 
and pituitary reserve loss, »981 
and placental glycogen metabolism, 
1185-1190 
and streptozotocin, »316 
PROGESTERONE 
and diabetic pregnancy, 34 
PROGESTIN 
and carbohydrate tolerance, »313 
PROINSULIN 
action, »57 
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in adipose tissue, 485 
and structure, 505 
amino acid sequences, 461-463, 465-466 
antibodies 
and insulin resistance, °368 
and antibodies to insulin, 656-657 
assay, *122 
biosynthesis 
and glucose, 538 
biosynthesis, intracellular transport, and 
conversion to insulin and C-
peptide, 572-579,581-583 
in blood, 661-670 
content of beta cell tumors, 535 
conversion to insulin, *314 
degradation 
in rats, 1091-1100 
and glucose metabolism 
in rat diaphragm and epididymal 
fat pads, 935-938 
and insulin 
conformational studies, 486-491 
-like component of insulin, °313 
and hypokalemia, * 1043-1044 
-like plasma components, 673-676 
metabolism, *347 
and C-peptide immunoreactivity, 1013-
1025 
porcine 
synthesis of related polypeptides, 476-
484, 485 
response to oral glucose 
and age, obesity, and degree of car-
bohydrate intolerance, °356 
structure 




and ornithine utilization studies in 
chick, *771 
PROPOXYPHENE 
and hypoglycemia, 960-961 
PROPRANOLOL 
and insulin 
and hypoglycemic coma, 960 
and insulin secretion, 783-784 
and blood sugar, *1120 
and liver carbohydrate metabolism, 
°1203 
and tolbutamide-induced insulin re-
sponse, *122 
PROSTAGLANDINS 
and blood flow and insulin output, *369 
and growth hormone secretion, *313 
and insulin release, *329 
PROSTATE GLAND 
hexokinase 
and testosterone, *185 
PROTEIN KINASE 
and cyclic AMP, 571 
PROTEINS 
adipose tissue noncollagen 
as index of cell number, °1201 
and amino acid flux into liver tissue, 
*316 
-bound carbohydrates 
and diabetes, 863-870 
deficiency 
in pregnant rats, *1041 
dietary 
and glucagon and insulin secretion, 
•912-913 
and glucagon biosynthesis, °58-59 
hepatic synthesis 
and tissue injury, °315 
insulin binding, 426 
and insulin release, 613, 617-618 
leucine incorporation of, *336 
of plasma very-low-density lipoprotein 
selenomethionine incorporation into, 
744-752 
rat liver nuclear 
and diabetes, *377 
restriction in pregnant rats 
and postnatal growth hormone pro-
duction and bone develop-
ment, *1047 
synthesis 
and alloxan diabetes, *339 
and cyclic AMP and hormones, *119 
and fatty acid synthetase activity, 
*914 
and insulin, 447-451 
and insulin and cyclic AMP, 453 
synthesis in anterior pituitary 
and insulin, *1200 
turnover in skeletal muscle 
and insulin, °341 
PROTEINURIA 
and glomerular lesions, °1120 
in Pima Indians, °365-366 
PROTEOLYSIS 
and cyclic AMP 
and insulin, 439-445 
PSEUDODIABETES 
and myopathy 
and capillary basement membrane 
thickening, *118 
PSORIASIS 
and carbohydrate metabolism, *250 
PURINE NUCLEOTIDE CYCLE 
and ammonia production, *1203 
PYRAZOLE 
and ethanol-induced fatty liver, *247 
PYRIDINE NUCLEOTIDES 
depletion 
and streptozotocin-induced diabetes, 
789-792 
and insulin release 
from toadfish insulin secretion gran-
ules, °983 




and glucose, *56 
PYRUVIC DEHYDROGENASE 




and pH of inflammatorv exudates, 
*1201 
and antibodies to insulin, 651-656, 657-
659, 660 
and blood sugar 
and insulin storage times, 812 
and insulin administration to gastroin-
testinal tract, 203-207 
and insulin response to amino acids 
and 2-cleoxy-D-glucose and manno-
heptulose, 1-5 
and iodinated insulin, °55 
and neutral Regular insulin, 242-245 
renal gluconeogenesis and ammonia 
production in, °57 
and serum insulin levels 
and trauma, *183 
and streptozotocin diabetes 
and islet cell changes, 129-137 
and thryotoxicosis 
and glucose utilization and insulin 
secretion, *370-371 
RACE 
and alcohol sensitivity, °254 
and lactose tolerance tests, 871 
RADIOIMMUNOLOGY 
in synthetic glucagon studies, 844-845, 
846-848, 855 
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RAT. See also Mystromys albicaudatus 
and acetoacetate 
and anemia, *311 
adipocytes 
fatty acid synthetase activity, °914 
adipose tissue 
glucose metabolism and insulin re-
sponse, 1151-1161 
and alloxan diabetes 
and arteriosclerosis, °1123 
and glycosaminoglycans metabolism, 
1162-1166 
and jejunal muscosa enzymes, *188 
and liver ribosomal aggregation, 84-
88 
and pressor response to angiotensin 
and norepinephrine, *354-355 
and 6-aminonicotinamide as diabeto-
genic agent, 143-148 
and ammonium chloride-induced aci-
dosis 
and glucose tolerance and insulin 
sensitivity, 794-796 
and blood sugar 
and nervous system sorbitol and fruc-
tose, 1173-1178 
brain 
glucose and D-3-hydroxybutyrate up-
take, *1206 
brain hexokinase, *1205 
brain utilization of ketone bodies, °247 
and carbohydrate and lipid metabolism 
and streptozotocin, °59 
cyproheptadine-treated 
and pancreatic beta cell alterations, 
71-78 
diabetic 
and calcium absorption, »983 
and connective tissue changes, 733-
743 
and insulin resistance, *1042 
and intestinal growth and hexose 
transport, °59 
and ketosis, 946-954 
and liver metabolism, 257-268 
and a-oxoglutarate carboxylation in 
liver mitochondria, °981 
and ventromedial hypothalamic de-
struction, *1043 
diabetic pregnancy in, *315 
and streptozotocin therapy, *316 
diaphragm and epididymal fat pads 
and insulin and proinsulin studies, 
935-938 
and diet 
and blood constituents and hepatic 
lipids, »1202 
and hypertriglyceridemia, »353-354 
and effects of maternal protein restric-
tion, »1047 
and ethanol-induced fatty liver 
and pyrazole and glucose, »247 
fasted and fed 
and amino acid levels, »119 
feeding response 
and brain calcium, »1046 
fetal development 
and diet and growth hormone, »189 
galactose-fed 
and nerve conduction defects, 295-
300 
gastrointestinal transport 
and glucagon, »983 
genetically obese 
and hyperinsulinemia and insulin re-
sistance, »838 
and glibenclamide, *55 
and glucose oxidation 
and diet and exercise, *179 
and glucose-U-C-14 and acetate l-C-14 
utilization for fat synthesis, 
»770 
heart 
lipoprotein lipase, »344 
high protein fed 
and liver gluconeogenesis, »358 
hyperammonemic 
and glucose metabolism, 0184 
and hyperglycemia 
and aminophylline, »775 
hypo-, hyper-, and euthyroid 
and ethanol and sorbitol metabolism, 
»181 
and hypothalamic stimulation 
and plasma glucose, insulin, and glu-
cagon, »771 
and insulin and proinsulin degradation, 
1091-1100 
and insulin secretion 
and phentolamine, °119 
islets of Langerhans 
adenyl cyclase and cyclic AMP phos-
phodiesterase, »328 
and alloxan and glucose, »326 
and ketone body metabolism, »246 
and kidney function 
and diabetes, °121 
and liver gluconeogenesis 
and glucose and insulin, »371 
and liver triglyceride biosynthesis 
and pregnancy and sex steroids, »365 
mammary cell metabolism 
and insulin, »315 
and microangiopathy, »357 
neonatal 
and diet and exocrine pancreas de-
velopment, »186 
newborn 
brain glucose metabolism in, »775 
and noradrenaline or adrenaline 
and blood glucose and free fatty acid 
responses to catecholamines, 
»912 
obese 
and insulin resistance and release, 
°316 
obese hyperglycemic 
and pancreatic beta cell uptake of 
amino acids, »772 
pancreas islet structure, 536-537 
and pancreatic hydrolases 
from birth to weaning, »59 
parabiotic 
differential feeder for, »983 
plasma glucose and free fatty acids 
and sodium pentobarbital, »836 
and plasma tryptophan 
and insulin, »909 
and portacaval shunting 
and glucose tolerance and serum 
immunoreactive insulin response, 
»179 
protein-deficient 
and kidney cellular development in 
progeny of, °1041 
salivary glands 
isoproterenol-stimulated, °982 
and serum triglycerides response to su-
crose and age, »835 
streptozotocin diabetic 
and U-C-14 glucose, xylitol, fructose, 
and sorbitol metabolism, *122 
and hyperphagia and polydipsia, 
•358-359 
and liver nuclear proteins, *377 
and urine glucolate, *372 
and tolbutamide 
and insulin secretion and, hypogly-
cemia, °1125 
and uremia 
and insulin release, *910-911 
and ventromedial hypothalamic nuclei 
destruction 
and glucose metabolism, •1204-1205 
and obesity, °1206 
Zucker "fatty" 
and insulin and obesity studies, »1123 
RAYNAUD'S PHENOMENON 
and insulin response to glucose, °837 
RESPIRATION 
and ketotic diabetes, 264-267 
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RETICULOENDOTHELIAL SYSTEM 
lipid metabolism and vascular clear-
ance in dogs, *312 
RETINA 
blood flow 
in children of diabetics and predia-
betes, *354 
of diabetic monkeys, 1086 
glycosaminoglycans 
and alloxan diabetes, 1163-1166 
and microangiopathy, *357 
RETINOPATHY, DIABETIC 
and argon laser photocoagulation, *189 
and bacteriuria, °118 
and blood platelet adhesiveness and ag-
gregation, • 120-121 
and diabetes control program, °382 
factors in progression of, °187 
and hypophysectomy, °349 
and pregnancy, 972-974 
in identical twins, °321-322 
and plasma growth hormone levels, 
°322 
and platelet aggregation, °355 
REYE'S SYNDROME 
and hypoglycemia, °248 
RHESUS MONKEYS 
and pregnancy 
and biliary lipids, 0912 
and plasma lipid levels, *774 
RHINOCERERRAL PHYCOMYCOSIS 
and diabetes, *185 
RNA 
binding to hepatic ribosomes 
and insulin deficiency, 84-88 
and insulin action, 455 
-messenger 
and insulin and liver metabolism, 
453 
pancreatic 
and diet in neonatal rats, *186 
synthesis 
and fatty acid synthetase activity, 
*914 
transfer-





RP 22410. See Glisoxepid 
RUBELLA 
congenital 
and diabetes incidence, * 248-249 
S 
SALICYLATES 
and hypoglycemia, 959-960 
SALIVARY GLANDS 
isoproterenol-stimulated 
and glucose metabolism, 0982 
SCHWANN CELL 
and aldose reductase, 299 
SCINTIPHOTOSCANS OF PANCREAS, 
°351 
SECRETIN 
and diuresis, *769 
and insulin release 
and acromegaly, °1118 
and pepsin secretion, *250 
release, *252 
and serum gastrin immunoassays, °249 
SELENIUM SCAN 
and insulinoma diagnosis, *1206 
SELENOMETHIONINE 




and diabetic impotence, 26 
SEMINOLES 
diabetes survey among, °776 
SEPHAROSE 
-bound insulin 
and muscle, adipose tissue and cul-
tured liver cells, *335-336 
SEROTONIN 
antagonists 
and insulin secretion, 779-787 
and insulin secretion in acromegaly, 
°352 
and carbohydrate tolerance 
and insulin secretion, °1200 
and insulin secretion, °184, °316 
SERUM 
N-acetyl-beta-glucosaminidase 
and diabetes, 1168-1171 
antiglucagon 
in synthetic glucagon study, 844-855 
anti-insulin 
assays, *769 
and enzyme histochemical studies of 
pancreatic islets, °911 
and hyperglucagonemia, °183 
and liver free fatty acid metabolism 
in dogs, 280-288 
betalipoproteins 
and abetalipoproteinemia, °60 
-bound insulin 
and insulin antisera, 930-934 
cholesterol 
and atherosclerotic disease, *253 
cholesterol and triglycerides 
and caffeine, °365 
and calcium, °980 
creatine, sodium and potassium 
and acidosis diagnosis, 1110 
creatinine 
in Pima Indians, °365-366 
free fatty acids 
and weight reduction, 758 
free fatty acids and glucose 
and L-dopa, *1121 
free fatty acids, insulin, and growth 
hormone 
and myocardial infarction, *119 
gastrin immunoassays 
and secretin, *249 
glucose 
in Mystromys alhicaudatus, 715-721 
glucose, ketones, immunoreactive in-
sulin and free fatty acids 
and sodium beta-hydroxybutyrate, 
*373-374 
glycoproteins 
and diabetes, 863-870 
growth hormone and Cortisol responses 
to graded insulin infusions, °379 
immunoreactive insulin 
and age, • 183-184 
and exercise, 104 
in genetically obese rats, *838 
in monkeys, 1078-1079, 1081 
in obese rats, *1123 
and portacaval shunt, *179 
response to glucagon, glucose and 
tolbutamide, 0121-122 
insulin 
and arginine, 308-310 
and insulinoma, *250 
in obese hyperglycemic mice, *119 
and trauma, *183 
insulin, cholesterol and triglyceride 
levels 
in obese diabetics, *361 
insulin and growth hormone 
and arginine and glucose, *316 
during oral glucose tolerance tests 
in children, 16-20 
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insulin responses 
differences between mongrel and 
beagle dogs, »356 
and small-vessel disease, °836 
insulin response to glucose 
and konnyaku ingestion, »60 
lipids 
in "acatalasemic" mice, »56 
and atherosclerosis, °253 
and metformin, »771 
in monkeys, 1078-1079 
nonsuppressible insulin-like activity, 
271-278 
osmolality 
and galactose toxicity syndrome, 
»315 
and plasma osmolality, lactic acid 
values and, °838 
C-peptide and proinsulin, 1013-1025 
phospholipids 
and diabetes, »123 
proinsulin and insulin, »347 
protein 
and diabetic microangiopathy, »371 
triglycerides 
response to fructose, age and, »835 
and sucrose and glucose, »58 
SEX 
and adipose tissue fat cell size and 
number, »180 
and blood glucose levels 
and exercise, 89-99 
and diabetic mortality, »1044 
and glucose tolerance tests in children, 
19 
and growth hormone secretion, »774-
775 
and muscle capillary basement mem-
brane changes, 883-896, 899-
905 
and serum glucose 
in Mystromys albicaudatus, 718, 719, 
720 
SEXUAL FUNCTION 
and diabetes, 23-28 
SHEEP 
renal glucose, free fatty acid and ke-
tone body metabolism in, 
»314 
SHOCK 
and fibrinolysis and peritoneal dialysis, 
»913 
hemorrhagic 
and insulin release, »364, »982 
traumatic 
and glucose metabolism, »1201 
S K I N 
bullous and atrophic lesions 
and diabetes, »251 
and diabetes 
and hyperinsulinism, 733-743 
fibroblasts 
glucose oxidation in, »360 
and glucose metabolism 
and insulin, »189 
glycosaminoglycans 
and alloxan diabetes, 1163-1166 
and lipid synthesis 
and starvation, alloxan diabetes and 
insulin, #189 
psoriasis 
and carbohydrate metabolism, »250 
toad 
and proinsulin action study, »57 
SLEEP 
growth hormone release during, »913 
SMOKING 
and hypoglycemia, 961 
SODIUM 
extracellular 
and glucose metabolism, 543 
and insulin secretion, 570, 861 
and pancreatic a-amino isobutyric acid 
transport, »181 
transport 
and proinsulin action, »57 
SODIUM ACETATE 
incorporation into lipids of rat aorta 
and insulin, »186 
SODIUM ACETATE I-C-14 
incorporation into rat aorta 
and insulin, »186 
SODIUM BETA-HYDROXYBUTYRATE 
and insulin secretion, »373-374 
SODIUM LINOLEATE 
and plasma free fatty acids, glucose, in-
sulin and ketones, 1179-1184 
SODIUM PENTOBARBITAL 




and cerebral edema during diabetic 
ketosis, »180-181 
and insulin release, 565 
metabolism 
in fasted and streptozotocin diabetic 
rat, »122 
and hypo-, hyper-, and euthyroid 
rats, °181 
in nervous tissues 
and blood sugar control, 1173-1178 
SORBITOL DEHYDROGENASE 
in human placenta, »330 
L-SORBOSE 
intestinal uptake, »249 
SPASMOLYTIC DRUGS 
and vein reactivity in diabetes, »909 
SPLANCHNIC NERVE 
stimulation 




and amino acid metabolism 
during pregnancy, * 1118-1119 
and carbohydrate, »772 
and diabetes treatment, 634 
and fat and lactate metabolism 
and insulin production, °1045 
and fetal metabolism, »187 
and glucagon secretion, »331-332 
and insulin and glucagon patterns, 
»359-360 
and insulin-induced hypoglycemia, 797-
803 
and jejunal mucosa enzymes, »188 
and ketone body metabolism, »246 
and kidney gluconeogenesis, »910 
and kidney sensitivity to mineralocor-
ticoid and glucagon, »334 
and lipid synthesis in rat skin, »189 
and lipolysis 
and iodinated insulin, »55 
and liver ketogenesis, 50-52 
and liver metabolism 
and glucagon:insulin ratio, »341 
and metabolism 
in streptozotocin diabetic rats, »122 
and plasma and tissue amino acids, 
»179 
and postheparin lipolytic and mono-
glyceridase activities, »54 
and tissue and islet cyclic AMP levels, 
»329 
STEROIDOGENESIS 
in isolated adrenal cells, »983 
STEROIDS 
-induced diabetic ketoacidosis, »54 
STREPTOZOTOCIN 
and beta cell membrane changes, »326 
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and carbohydrate and lipid metabo-
lism, *59 
and diabetic pregnant rats, *316 
and glucose metabolism 
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Opposi te K i n e t i c s of L - L e u c i n e a n d 
L - P h e n y l a l a n i n e I n d u c e d I n s u l i n Re lease 
Studied wi th the P e r f u s e d R a t P a n c r e a s 
R. L A N D G R A F , M. L A N D G R A F - L E U R S , 
P. SCRIBA, and K. S C H W A R Z (Introduced by 
E. F. P F E I F F E R * ) , Munich, Germany 
Little is known about the dynamics of insulin release 
provoked by amino acids. Therefore isolated pancreases 
were perfused with saline-dextran buffer, containing leu-
cine or phenylalanine, without recycling. Samples were 
taken at short intervals and the amount of insulin was 
measured by an immunoassay. In the absence or presence 
of substimulatory levels of glucose, 10 and 20 mM 
leucine caused a biphasic pattern of insulin secretion, 
comparable to that of 20 mM glucose. When leucine 
was perfused together with 20 mM glucose no significant 
additive effect could be observed. However when glucose 
plus leucine were perfused after an initial stimulatory 
period with leucine alone, a typical biphasic response 
was again observed and the additive effect was more 
pronounced. In contrast, phenylalanine provoked no in-
sulin release in the absence of glucose. In the presence 
of 2.5 m M glucose, a burst of insulin output occurred 
after removal of the phenylalanine from the perfusate. 
When phenylalanine (10 or 20 m M ) was added during 
the second phase of the glucose-induced insulin release, 
it potentiated the glucose effect after an initial inhibition. 
These data suggest the existence of more than one 
receptor for amino acids for the stimulation of insulin 
secretion, comparable to, but not necessarily identical 
with the carbohydrate receptors. Assuming that leucine 
and phenylalanine use the same transport system (D.L. 
Oxender, and H. N . Christensen, J. Biol. Chem. 238: 
3686, 1963) our data indicate that the receptor sites 
for the stimulation of insulin secretion by amino acids 
may not be transport sites. 
